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The failing aortic valve in adults:
where do we stand?
Filip P.A. Casselman M.D.
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Introduction
In order to understand the physiology and pathophysiology of the aortic valve, one needs
to be aware of the normal anatomy of the aortic valve and the most commonly seen
structural deviations. This review will therefore first focus on the anatomy of the aortic
valve and its most frequent abnormalities. Subsequently, the possible pathological
conditions of the aortic valve will be discussed. Finally, the various treatment modalities
for correction of the failing aortic valve will be presented. As this thesis focuses on
reconstructive surgery of the adult aortic valve, this chapter will accordingly be limited
to adults. 
Anatomy and function of the normal aortic valve 
The normal aortic valve is a structure consisting of three freely mobile cusps, located
between the left ventricular outflow tract and the tubular portion of the aorta [1]. These
three cusps together form a thin, mobile layer of tissue which, by opening, allows free flow
of blood from the left ventricle into the aorta during systole, and which prevents, by closing
during diastole, regurgitation of blood from the aorta back into the ventricle. The three
aortic valve cusps are designated right, left and non-coronary cusp according to the
respective coronary artery or the absence of an originating coronary artery from the sinus
which they face. The size of the three cusps is usually unequal with the non-coronary cusp
commonly being the largest and the right coronary cusp being the smallest [1-4]. In 16%
of cases, the three aortic valve cusps are equal in size [1].
The aortic valve cusps are not attached in a circular horizontal plane to the aortic wall
but in a semilunar fashion. This line of attachment, also called the annulus fibrosus,
constitutes the physiologic ventriculo-arterial junction and is in fact a coupled sequence
of three paraboloids [5] (Fig. 1). This physiologic ventriculo-arterial junction is different
from the anatomical ventriculo-arterial junction being the straight horizontal circle where
the fibro-elastic aortic wall joins the supporting structures of the left ventricle (Fig. 1) [6-7]
or, beneath the non-coronary cusp, the aortic-mitral fibrous continuity. The area between
the physiological and the anatomical ventriculo-arterial junction is made of fibrous tissue
and forms three interleaflet triangles between the longitudinal limbs of the annulus fibrosus.
These interleaflet triangles are thus situated underneath the line of attachment of the valve
cusps and are therefore exposed to ventricular hemodynamics.
Each aortic valve cusp contains a hinge point, a body and a coapting surface (lunula)
with a thickened central nodule, the nodule of Arantius. The hinge point is the area where
the leaflet is attached to the aortic root in the earlier mentioned semilunar fashion. The top
of these attachments is called the ‘commissure’ and is situated at the level of the sinotubular
junction whereas the bottom (the so-called nadir) is situated below the anatomical
ventriculo-arterial junction. 
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Figure 1: Diagram of the aortic root. The coronetlike arrangement of the valvar attachments. (From:
Sutton III JP, et al. The forgotten interleaflet triangles: a review of the surgical anatomy of the aortic valve.
Ann Thorac Surg 1995;59:419-27. Reprinted with permission from The Society of Thoracic Surgeons).
The function of the aortic valve cannot be separated from the more complex setting of the
aortic root. The aortic root comprises the initial portion of the ascending aorta and is limited
inferiorly by the anatomical ventriculo-arterial junction and superiorly by the sinotubular
ridge or sinotubular junction which delineates the beginning of the proper ascending aorta.
The components of the aortic root are thus the three sinuses of Valsalva, the interleaflet
triangles and the valve cusps [6-9]. The three sinuses of Valsalva are designated left, right
and non-coronary according to the aortic valve cusp they face and they are limited
superiorly by the sinotubular ridge. The sinuses of Valsalva were already recognized by
Leonardo da Vinci who realized their importance in correct aortic valve functioning [10].
Indeed, the aortic valve/root is a dynamic structure in which most geometric parts are
continuously changing during a cardiac cycle in response to aortic pressure (which is also
determined by the peripheral resistance), ventricular pressure and ventricular geometry
[2, 11]. More precisely, due to the global left ventricular contraction during systole, there
is an inward movement of the physiologic ventriculo-aortic junction, resulting in a
reduction of its diameter. In addition there is an outward movement of the commissures.
This change is supposed to facilitate systolic blood expulsion from the left ventricle [3,
9, 11]. During diastole, the opposite movement takes place and the aortic valve closes. The
diastolic aortic pressure provides blood flow into the coronary arteries. The correct
functioning of the aortic valve complex is an interaction of all of its components including
the ventriculo-aortic junction, the aortic valve leaflets, the sinuses of Valsalva and the
commissures with their apex reaching the sinotubular ridge. The importance of the diameter
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of the sinotubular ridge was already recognized in 1832 by Corrigan who suggested that
a dilatation of the sinotubular junction, frequently a result of ascending aortic aneurysm,
was probably the cause of aortic regurgitation [12]. This pathophysiologic mechanism has
been accepted since several years by cardiac surgeons and has recently been confirmed
experimentally [13]. 
Anatomical variations
Congenital bicuspid aortic valve is the most frequent structural anomaly of the aortic valve.
Its frequency in the general population however is not exceeding 0.4 to 2% [14]. There
are two types of congenital bicuspid aortic valve: the cusps are either located right and left
with the commissures being anterior and posterior or the cusps can be located anteriorly
and posteriorly with the commissures being right and left [14-15] (Fig. 2).
Figure 2: Diagram showing the two basic types of congenitally bicuspid aortic valves. (From: Roberts
WC. The congenitally bicuspid aortic valve: a study of 85 autopsy cases. Am J Cardiol 1970;26:72-83.
Reprinted with permission from Exerpta Medica Inc.).
 
Approximately 50% of congenital bicuspid valves have so-called false raphes [16]. A raphe
is a ridge of tissue which partially divides one of the cusps of the bicuspid valve and which
lies vertically in the wall of the aortic sinus. Although congenital bicuspid aortic valve is
generally not considered to be inherited, there is a high incidence of familial clustering
[17]. Besides the congenital bicuspid aortic valve, most authors also distinguish the so-
called acquired bicuspid aortic valve. This type of valve originates from a trileaflet aortic
valve in which fusion of two adjacent cusps occurred. This fusion constitutes a ‘new’ raphe,
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and it is sometimes difficult to differentiate these two types of bicuspid aortic valves [14,
16, 18]. The majority of the bicuspid aortic valves belong to the acquired type of bicuspid
valve as evidenced by the presence of three interleaflet triangles [7, 18].
Other anatomical variations are the unicuspid or quadricuspid aortic valve [16].
Unicuspid or quadricuspid valves occur very rarely but frequently develop stenosis or
regurgitation throughout life. 
Histology
 
of the aortic valve and root wall
The aortic valve leaflet consists of three distinctive connective tissue layers covered by
an endothelial cell layer on both the aortic and the ventricular side of the leaflet [19-20].
These three layers are the lamina fibrosa which is on the aortic side of the leaflet, the
lamina spongiosa which is the middle layer and the lamina ventricularis which is on the
ventricular side of the leaflet [21]. 
The lamina fibrosa is a dense layer of collagenous chords starting at the level of the
commissures and running in circumferential direction towards the middle of the leaflet
where the chords divide in smaller fibers forming a meshwork. The free edge of the leaflet
is especially dense in collagenous fibers. The lamina fibrosa supports most of the diastolic
pressure.
The lamina spongiosa is the middle layer which serves as a shock-absorber layer [21-22].
To fulfil this role, this layer contains only very few fibers but is composed of loose
connective tissue mainly consisting of proteoglycans. The lamina spongiosa is relatively
thick in the center of the leaflet but thins out towards the free edge. 
The lamina ventricularis is a very thin layer consisting mainly of elastin fibers which
are oriented in radial direction. Additionally, this layer contains smooth muscle cells. The
lamina ventricularis is connected to the ventricular outflow tract [21]. 
The valve leaflet tissue is in constant tissue renewal and this tissue turn-over is maximal
in the regions where stress is highest e.g. along the hinge point. This tissue turn-over is
probably important to resist tissue wear [16]. 
A recent study demonstrated the vascularization of the aortic valve [23]. Vessels were
found predominantly in the basal third of the cusps and extended in from the commissures
almost to the level of the free edge. There was a significant difference between the presence
of vessels in the basal part and the mid and free edge regions of the valve. There was no
difference among the three cusps. 
Innervation of the aortic valve arises from the ventricular endocardial plexus and is
located in the lamina ventricularis [24]. The entire cusp contains nerve fibers with the
exception of the coapting edge. The non-coronary cusp, which has no underlying
ventricular endocardium, receives its innervation from the adjacent valve leaflets. Its
innervation however is less dense than that of the two other cusps. The overall density of
innervation decreases with age. It is unclear whether the innervation of the cusps plays a
role in proper valve functioning [24]. 
Chapter 1
14
The histology of the aortic root is characterized by a gradual shift from the muscular
ventricle to the primarily elastic aorta [6]. The ascending aortic wall itself contains 3 layers
which are, from intraluminal to extraluminal, the intima, the media and the adventitia. The
media has a predominant circular ‘lamellar’ elastic architecture which is immediately
proximal from the sinotubular ridge and further towards the aortic annulus, progressively
interrupted by increasing amounts of collagenous tissue. The layers of elastic tissue
eventually become thinner and subsequently disappear. It is at this level that the dense
collagen bundles form the aortic annulus [6].
Pathological conditions of the aortic valve
These can either be aortic stenosis, aortic regurgitation or a combination of both, the so-
called combined or mixed aortic valve disease. This paragraph will focus on the
pathogenesis of aortic stenosis and aortic regurgitation. Mixed disease will not be discussed
as this is a combination of both pathological conditions in a variable degree. 
Aortic stenosis
Although aortic valves can become stenotic from several different causes, the large majority
of them becomes stenotic because of congenital malformation or degenerative calcification
[25-26]. Isolated aortic stenosis, in the absence of mitral valve disease, is uncommon in
rheumatic heart disease [14, 16, 25-26]. The pathogenesis of rheumatic aortic valve disease
is further explained in the section on aortic regurgitation. 
Degenerative changes in the human body also affect the aortic valve and root. Aging
causes a thickening of the collagen fibers in the aortic valve leaflets. These fibers also seem
to lose their predominantly circumferential orientation [27]. In addition, aging aortic valves
have an increased number of elastic fibers but this is most likely due to fragmentation rather
than to an increase in the number of fibers present [28]. Other age-related changes include
an accumulation of cellular degradation products such as lipids and calcium. This is
probably due to an insufficient microvascular scavenging mechanism in the valve leaflets
[29]. The presence of these cellular degradation products will increase the rate of
calcification [29-30] and this phenomenon occurs initially at the sites of the highest
mechanical stress in the aortic valve leaflets [31-32]. These areas are the hinge point of
the aortic valve leaflet and the commissural area [31]. Once calcification is initiated at the
leaflet attachment line, stress distribution on the remaining parts of the aortic valve leaflet
is changed and the calcification then usually progresses along the line of coaptation [16].
These aging changes in the aortic valve leaflet result in an increasing valve thickening,
stiffness and a decrease in extensibility of the valve leaflet [27, 29, 33-34]. 
Although up to 64% of patients with a bicuspid aortic valve have a normal life span without
ever developing aortic valve pathology, about 50% of patients with aortic stenosis have
a bicuspid aortic valve [25, 35-37]. The presence of a raphe might change the stress
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distribution characteristics of the leaflet and therefore lead to calcification. However, the
exact mechanism of calcification in bicuspid aortic valves is unknown. Edwards [38]
suggested a mechanical trauma in the pathogenesis of bicuspid aortic valve stenosis. Indeed,
the length of the free edge of the two valve leaflets is usually unequal. This unequal length
creates abnormal contact between the two leaflets which in turn produces tension or
mechanical trauma to the leaflet. This will result in focal fibrous thickening leading to
dystrophic calcification. This hypothesis explains stenosis as a result of leaflet trauma but
does not explain why other bicuspid aortic valves perform satisfactorily throughout a
normal life span.
Aortic stenosis is considered the most frequent complication of a bicuspid aortic valve.
Its clinical manifestation at a mean age of 56 to 59 years is earlier than in degenerative
aortic stenosis (mean age of 62 to 72 years) whereas aortic stenosis in unicuspid valves
occurs at an average age of 48 years [25]. 
Some other rare causes of aortic stenosis include Paget’s disease, and end stage renal
disease which both result in calcific aortic stenosis [39-40]. This subtype of aortic stenosis
is an extreme form where the whole leaflet surface is calcified. Another rare cause of aortic
stenosis is ochronosis, an inherited metabolic disorder [41]. 
The natural history of aortic stenosis in the adult is characterized by a prolonged latent
period in which morbidity and mortality are very low [42-44]. Medical therapy during this
time interval mainly consists of afterload reduction. The rate of progression of aortic
stenosis is impossible to predict for a specific patient but the decrease in valve area is
usually around 0.12 cm  per year or an increase in pressure gradient across the valve of2
about 15 mm Hg per year [42]. The development of symptoms such as angina, syncope 
or heart failure identifies a critical point in the natural history of aortic stenosis [42-44].
After the onset of symptoms, survival averages two to three years. Patients in heart failure
due to a deteriorating left ventricular function are dead within one to two years. Sudden
death is also possible in patients with aortic stenosis but has hardly ever been documented
in patients without prior symptoms. Deteriorating left ventricular function or the onset of
symptoms are therefore strong indicators for operative management of aortic stenosis. 
The diagnosis of aortic stenosis is usually confirmed by echocardiography and/or
angiography. Stress tests have proved to be unreliable, especially with coexisting coronary
artery disease. The severity of aortic stenosis is expressed as a pressure gradient between
the left ventricle and the aorta as wel as a measurement of the (reduced) aortic valve orifice
area. Currently, an aortic valve area < 1 cm  and/or a ventricular-aortic gradient of > 502
mm HG, are considered an operative indication in asymptomatic patients with normal left
ventricular function. Symptomatic patients or patients with a deteriorating left ventricular
function due to aortic stenosis should be operated within a short time frame, even though
the above criteria might not be matched. Accordingly, patients with milder disease may
undergo concomitant aortic valve surgery when other indications for heart surgery
necessitate earlier intervention [42-44]. 
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Aortic regurgitation
Aortic regurgitation may result from diseases from either the aortic valve, the ascending
aorta or both [45]. The most common causes of aortic regurgitation in this study were aortic
root dilatation (37%), postinflammatory or rheumatic disease (29%), incomplete closure
of a congenitally bicuspid aortic valve (24%), and infective endocarditis (6%). 
In rheumatic fever, the aortic valve cusps become infiltrated with fibrous tissue, and
retract. This causes failure of cusp coaptation during diastole and consequently, central
aortic regurgitation will result [46]. The associated fusion of the commissures may also
restrict aortic valve opening, resulting in combined aortic valve stenosis and regurgitation.
As stated earlier, associated mitral valve disease is the rule in rheumatic heart disease. 
Other primary valvular causes of aortic regurgitation include incomplete closure and/or
leaflet prolapse of a bicuspid aortic valve. It is true that the most frequent complication
of a bicuspid aortic valve is stenosis [16, 25, 44] but nevertheless, bicuspid aortic valve
is the major cause of isolated aortic regurgitation, especially in the absence of ascending
aortic or aortic root dilatation [47]. Moreover, regurgitant bicuspid aortic valves tend to
occur at a younger age than stenosis [35]. The cusp prolapse usually affects the leaflet
containing the raphe since the free edge of this leaflet is longer. Although much less
frequent, cusp prolapse may also occur in tricuspid aortic valves [48]. 
Infective endocarditis may destroy, or cause perforation of a leaflet; alternatively,
vegetations on the valve leaflets may interfere with proper cusp coaptation. All of these
will lead to massive aortic regurgitation [44]. 
Less common causes of aortic valve regurgitation include trauma, rupture of a
congenitally fenestrated valve and aortic regurgitation associated with systemic diseases
like lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, Syphilis and
Takayasu’s disease or associated with Whipple’s and Crohn’s disease [44]. Aortic
regurgitation associated with prosthetic valve replacement will not be discussed here. 
The incidence of patients undergoing surgery for pure aortic regurgitation secondary to
aortic root disease with subsequent dilatation has steadily increased over the years and now
accounts for about 50% of the cases [26]. Various conditions affecting the aortic wall
produce dilatation of the sinotubular junction with secondary central aortic regurgitation
[13]. Age-related changes affecting the aortic root and the ascending aorta include
accumulation of ground substance, fragmentation of elastic fibers, gradual replacement
of smooth muscle cells with collagen and focal medial necrosis [49]. The overall result
is an increasing stiffness of the aortic root which also tends to dilate with age [50]. 
Other pathological conditions associated with dilatation of the aortic root include aortitis
[51-54], Marfan syndrome [55], aortic dissection [56], hypertension [57], or other diseases
associated with connective tissue abnormalities such as cystic medial necrosis [58], Ehlers-
Danlos syndrome [59] or osteogenesis imperfecta [60]. All of these conditions do not
primarily affect the aortic valve but the dilatation of the root and the resulting central aortic
regurgitation may secondarily affect the valve leaflets which may thicken and retract,
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thereby increasing the existing degree of regurgitation [44]. Interestingly, isolated dilatation
of one or more of the sinuses of Valsalva without dilatation of the sinotubular junction does
not cause aortic regurgitation [13]. Aortic regurgitation in association with a peri-
membranous ventricular septal defect is an almost exclusively pediatric entity and will
therefore not be discussed here.
The natural history of aortic regurgitation in patients with acute aortic regurgitation is
different from patients with a gradual progressive ‘chronic’ aortic regurgitation [42-44].
Even a normal ventricle cannot sustain an acute severe volume overload. The risk of acute
aortic regurgitation is therefore much higher than that of chronic aortic regurgitation and
patients with acute regurgitation should promptly be referred for surgery since they will
rapidly develop pulmonary edema and cardiogenic shock. 
In contrast, chronic aortic regurgitation, even when severe, may be well tolerated for
several years. Medical therapy in patients with normal left ventricular function should,
besides diuretic therapy, also consist of afterload reduction since this diminishes the
regurgitant volume and has been proven to delay the need for aortic valve replacement [43].
Patients with chronic aortic regurgitation should be followed echocardiographically at
regular intervals to detect any progression of the disease, which is generally unpredictable.
The onset of left ventricular dysfunction is an early marker of subsequent symptoms such
as angina, dyspnea and heart failure. As in aortic stenosis, once the patient becomes
symptomatic, the condition often deteriorates rapidly and survival in patients with heart
failure generally does not exceed two years. Sudden death may occur but is not frequent
and usually does so in previously symptomatic patients [42-44]. 
Aortic regurgitation is usually confirmed echocardiographically [61] and angio-
graphically. Current indications for surgery include acute aortic regurgitation, severe
regurgitation, whether or not in association with symptoms or a dilated left ventricle, left
ventricular dysfunction and symptomatic patients [42-44, 62].
Surgical options for the failing aortic valve
Aortic stenosis
& Repair procedures
Although the majority of stenotic aortic valves will require valve replacement, there are
some indications for ‘alternative’ techniques. Balloon aortic valvuloplasty initially relieves
obstruction in most patients but restenosis due to scarring occurs in about half of the
patients within 6 months [63]. Its role is currently limited to the management of severe
aortic stenosis in non-surgical candidates such as patients requiring an urgent non-cardiac
operation, in pregnant women, in patients refusing surgical treatment or as ‘bridge’ to aortic
valve replacement in patients with severe heart failure, and an otherwise high operative
risk [64-65]. 
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Initial attempts for the repair of calcific aortic valve stenosis were carried out in the late
fifties and early sixties [66]. Cusp perforation and postoperative aortic regurgitation were
frequent problems and the technique was abandoned when mechanical valve prostheses
became available. However, with the increasing experience and improving results of mitral
valve repair [67], renewed interest in aortic valve repair became apparent. This mainly
included aortic valve repair for regurgitation of different origins (see further). Some authors
also attempted aortic valve repair in calcific or degenerative aortic valve stenosis, either
by manual debridement [68-69] or with the aid of electrohydraulic shock waves or
ultrasonic therapy [70-73]. Although decalcification as such is technically feasible and has
the benefit of avoiding oral anticoagulation, early recalcification is not prevented [74].
Restenosis after manual debridement may lead to reoperation in up to 25% of the patients
at 5 years [69]. These unacceptable results currently exclude widespread use of manual
aortic valve debridement. Aortic valve debridement with the aid of electrohydraulic shock
waves or ultrasonic therapy equally leads to unacceptable results since restenosis or aortic
regurgitation occur in the majority of patients at short-term follow-up [71-72]. 
Duran has been the proponent of aortic valve repair in a predominantly rheumatic patient
population. Since most of his reports deal with valve repair for rheumatic aortic
regurgitation, some with associated aortic stenosis, but not for pure aortic stenosis, this
topic will be discussed in the section on valve repair for aortic regurgitation. 
In summary, aortic valve repair for predominantly aortic stenosis has been disappointing,
and largely abandoned in favour of valve replacement. 
& Valve replacement options
The present paragraph aims to give a brief overview of the currently available valve
substitutes while focussing on the main issues for each category rather than going into detail
on all available types of valve substitutes for each category.
1) Mechanical aortic valve replacement. Since the first successful mechanical aortic valve
replacement by Harken et al. in 1960 [75], a whole scala on mechanical valve prostheses
has been developed and tested clinically. From all pioneering devices, only the Starr-
Edwards® valve stood the test of time, and its Silastic ball valve model 1200 and 1260
is currently still implanted. The long-term performance (up to 31 years) of this valve was
recently documented by Lund et al. [76]. No structural failures were seen in their series,
and the incidence of valve related complications was as follows: thrombo-embolism
2%/patient-year (pt-year), valve thrombosis 0.06%/pt-year, anticoagulation related bleeding
2.08%/pt-year, endocarditis 0.38%/pt-year, paravalvular leak 0.26%/pt-year, hemolysis
0.1%/pt-year for a total of any valve related complication of 4.89%/pt-year. When only
major complications were considered, the incidence was 2%/pt-year. 
In order to further improve the clinical performance of mechanical heart valves, first
the tilting disk [77-78], and later the bileaflet valve design was proposed which ultimately
resulted in the St Jude Medical heart valve, clinically introduced in 1977 [79]. Intermediate
and longer term follow-up of this model established its clinical domination [80-82], and
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provoked competitors to design other bileaflet prostheses aiming to offer the patient a better
and safer valve prosthesis [83-89]. Reported figures of valve related complications depend
of course on the size and characteristics of the patient cohort and the duration of follow-up.
Overall, the clinical performance of the currently available bileaflet aortic valve prostheses
is rather good: structural failure is hardly ever reported; thrombo-embolic and anti-
coagulation related bleeding events are both in the range of 1 to 1.5%/pt-year; valve
thrombosis is rare and its incidence is around 0.06%/pt-year; endocarditis is less then
0.5%/pt-year; hemolysis accounts for approximately 0.1%/pt-year and paravalvular leak
for approximately 0.25%/pt-year; finally, the aortic valve reoperation incidence is slightly
less than 1%/pt-year.
In summary, the currently available mechanical aortic valve prostheses perform
satisfactory but are not free from valve related complications. Patients need life-long
anticoagulation and to date, it remains uncertain what the clinical impact will be on the
very long-term.
2) Bioprosthetic valve replacement. Bioprostheses do not require permanent anticoagulation
and therefore minimize the risk of trombo-embolism and anticoagulant related bleeding
that is inherent to all mechanical prosthetic valves. Besides, they also obviate the practical
inconveniences associated with permanent anticoagulation.
Numerous stented bioprostheses have been introduced in clinical practice during the
past three decades. The second generation bioprostheses of the early eighties (Hancock
II® porcine bioprosthesis, and the Carpentier-Edwards Perimount® pericardial
bioprosthesis) have better hemodynamic features and appear to be more durable than the
first generation bioprostheses of the seventies (Standard Hancock®, Hancock MO® and
Carpentier-Edwards® porcine bioprostheses)[90]. Whether this can be solely attributed
to the lower pressure fixation in the more recent series is beyond the scope of this review.
Myken et al. demonstrated a substantial reduction of valve related complications in
bioprostheses when compared to bileaflet mechanical valve prostheses. The 10-year
freedom from valve related complications in the bioprosthesis group was 74% versus 59%
in the mechanical valve group [91]. 
The major problem with stented bioprostheses however is their limited durability. Cuspal
tears, degeneration, perforation, fibrosis and calcification are possible complications which
seem to occur more frequently in the younger patient population as opposed to a more
elderly patient group [92-93]. This is probably due to the increased calcium metabolism
in the younger patient group. 
Currently, the Carpentier-Edwards® bovine pericardial valve is the most frequently used
aortic valve bioprosthesis. Its low incidence of valve related complications, associated with
a freedom of structural valve deterioration of 93% at 12 years in patients older than 65
years of age, makes this prosthesis the valve substitute of choice in this age group [94].
In order to improve the available stented bioprostheses, much attention and effort has
been spent during the past decade in the development of stentless (mostly porcine)
bioprostheses. These valves have better hemodynamic properties than stented bioprostheses,
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and they also seem to have a more substantial beneficial effect on restoring left ventricular
mass and function [90]. Besides, they may have a reduced medium-term mortality rate as
compared to stented bioprostheses [95]. Whether the long-term durability will also be
enhanced remains to be proven.
Stimulated by the favourable results with the Carpentier-Edwards® bovine pericardial
valve, efforts have been undertaken to design a stented bioprosthesis made intra-operatively
of autologous gluteraldehyde fixed pericardium. Results with this technique however have
been disappointing and the idea was abandoned [96].
In summary, bioprosthetic valves obviate permanent anticoagulation, have a low
incidence of trombo-embolic and bleeding complications but are limited by a substantial
incidence of structural failure in patients of less than 65 years of age.
3) Homograft valve replacement. Homografts share the advantage of bioprostheses in
avoiding the need of anticoagulation. Consequently, they have a very low thrombogenicity
rate. Their hemodynamics are superior to those of stented bioprostheses and their clinical
performance is excellent [97-99]. The incidence of valve related complications was given
in the study by Lund et al. [99]: anticoagulant-related bleeding 0.09%/pt-year; embolism
1.4%/pt-year; endocarditis 0.6%/pt-year and tissue failure 4.5%/pt-year.
Limited availability and tissue failure restrict the use of homografts. Indeed, the overall
freedom from tissue failure in the study from Lund et al. was 62 and 18% at 10 and 20
years respectively. This was however highly dependent on donor and recipient age with
the best freedom of tissue failure obtained in a 70 year old recipient and a 30 year old
donor. In this case, freedom from tissue failure was 91 and 64%, also at 10 and 20 years.
Also, the technique of homograft insertion seems an important predictor. Basically, two
techniques are used for homograft implantation: the subcoronary and the root replacement
technique. In the paper by Lund et al. the root replacement group did significantly better
with regard to tissue failure and subsequent aortic valve reoperation incidence. Freedom
from tissue failure at 15 years in the root replacement group was 56% versus 33% with
the subcoronary technique. The fact that their patient population mainly consisted of
subcoronary implants may have adversely influenced the overall results of this study.
Homografts are currently mainly indicated as root replacement in the treatment of native,
or prosthetic valve endocarditis with excellent clinical results and a freedom from recurrent
endocarditis of 98% at 5 years [100].
4) Pulmonary autograft for aortic valve replacement (Ross procedure).The use of the
autologous pulmonary valve to replace the aortic valve was first described by Ross in 1967
[101]. A homograft is then used in the pulmonary position to replace the patients’ own
pulmonary valve. The initial technique employed a subcoronary implantation, and long-
term follow-up of the initial series showed a 23% reoperation rate for severe regurgitation
of the autograft [102]. Currently, most authors use the root replacement technique while
some favor the inclusion technique [103-104]. The advantages of the pulmonary autograft
over the homograft include increased cellular viability and therefore possible enhanced
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durability; an additional advantage is the growth potential of the autograft in children [103].
However, as this procedure implies a double valve replacement, the operation is technically
much more complex and demanding than the homograft aortic valve replacement.
Therefore, the Ross procedure is currently considered the valve substitute of choice in
children and young adults. In a recent report by Elkins et al. [105] the freedom from
autograft reoperation was 90% at 8 years and the freedom from reoperation on the
homograft in the pulmonary position was 94%, also at 8 years. There were no other valve
related complications such as thrombo-embolism, bleeding or endocarditis. 
A point of concern exists with regard to dilatation of the pulmonary autograft when used
as a root replacement. This dilatation occurs immediately postoperatively and progresses
somewhat further during follow-up [106]. However, when the inclusion technique is used,
the dilatation seems much less and growth potential is preserved [103]. 
Aortic regurgitation
& Repair procedures 
Although some attempts were made in the early years of cardiac surgery to repair
insufficient aortic valves [107-109], it is only in the eighties that recurrent interest resulted
in consistent techniques with regard to specific pathological conditions. 
The incidence of rheumatic fever has markedly decreased in Western Europe and
Northern America [45], but in some parts of the world, it is still considerable. It is in this
patient population that Duran developed his reconstructive techniques for predominantly
regurgitant, rheumatic aortic valve disease. He applied these repair techniques in patients
undergoing surgery primarily for mitral valve disease, and in whom it was desirable to save
the aortic valve, particularly when a mitral valve repair had been possible. In a series of
publications [110-114] he described his techniques. In rheumatic aortic valvular disease,
regurgitation is mainly caused by decreased cusp mobility (Fig. 3). At the level of the
commissure, increased mobility can be obtained by calcium excision and/or
commissurotomy. Moderate leaflet edge retraction can be suppressed by free edge
unrolling, or shaving whereas severe retraction will need cusp extension with autologous
pericardium. Finally, Duran often adds a sinotubular ridge enhancement since this induces
an earlier aortic valve closure [115] (Fig. 3). 
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Figure 3: Diagram of aortic valve lesions and corresponding repair techniques. Aortic regurgitation with
decreased cusp mobility. (From: Duran CMG. Aortic valve repair and reconstruction. Oper Techn in
Cardiothorac Surg 1996;1:15-29. Reprinted with permission from W.B. Saunders Company and CMG
Duran).
Although early and mid-term follow-up results reported by Duran were encouraging [110-
114], and prompted further investigation of the applicability of these techniques, at least
by himself, virtually no other authors have reported similar results on this topic which
questions the reproducibility of these surgical strategies. In addition, a recent report by
Bernal et al., who did a follow-up study of the initial patient population operated by Duran
in Spain, showed a disappointingly low freedom from repaired aortic valve structural
deterioration of 25.3% at 22 years [116]. 
For the above mentioned reasons, it is questionable whether there remains any place
for aortic valve repair in rheumatic valvular heart disease, except in countries where
adequate control of anticoagulation is not feasible. 
Other pathological conditions leading to aortic regurgitation, such as cusp prolapse, aortic
root and/or sinotubular dilatation regardless of the cause, are more amenable to repair and
they constitute the basis of this thesis. Cusp perforation due to endocarditis, reparable with
a patch of autologous pericardium, is not further described since this occurs only very
seldom. 
& Aortic valve replacement
All devices used for aortic valve replacement in aortic stenosis are also applicable in aortic
regurgitation. However, results of the Ross procedure for pure aortic regurgitation show
an increased rate of recurrent aortic regurgitation during follow-up when compared to aortic
stenosis as operative indication [117]. At presence, it is yet unclear whether the Ross
procedure should be limited to patients with aortic stenosis. 
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Combined aortic stenosis and regurgitation
The etiology and morphology in this group is similar to that of aortic stenosis. Accordingly,
treatment principles and options follow [118]. 
Aim of the present thesis
Given the poor results of aortic valve repair in aortic stenosis, and rheumatic aortic
regurgitation as discussed above, the present thesis focuses on possible indications for adult
aortic valve repair in regurgitation due to other causes. Chapter 2 examines the results of
bicuspid aortic valve repair for leaflet prolapse, whereas chapter 3 looks at the results of
leaflet prolapse repair in tricuspid aortic valves. Chapter 4 studies the durability of aortic
valve preservation in Type A dissection, and chapter 5 reports the initial results of the aortic
valve reimplantation technique for the treatment of aortic regurgitation due to dilatation
of the aortic root and sino-tubular junction. The present thesis investigates the feasibility
and the durability of all these procedures. Essential in these reparative techniques is the
presence of (near to) normal valve tissue in order to obtain the best result possible. 
All of these techniques avoid the need for permanent anticoagulation. If durability of the
techniques could be demonstrated, avoidance of anticoagulation might be an additional
benefit, particularly if applied in young patients who still have a long life-expectancy. In
order to study the incidence, frequency and severity of very long-term anticoagulation
related complications, a follow-up study was undertaken of all patients undergoing a
mechanical aortic valve replacement at the St. Antonius Hospital in Nieuwegein, The
Netherlands between December 1963 and January 1  1974, representing the first 10-yearst
experience of mechanical aortic valve replacement at this institution. This study is the
subject of chapter 6.  
Chapter 7 is a discussion of the obtained results and a correlation with clinical practice.
Finally, chapter 8 is a summary of the present thesis. 
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Abstract
Objective: To determine the durability of repair of a bicuspid aortic valve with leaflet
prolapse, and to identify factors associated with repair failure. 
Methods: From November 1988 to January 1997, 94 patients with a bicuspid aortic valve
and regurgitation from leaflet prolapse had aortic valve repair. In 66 patients, the repair
employed triangular resection of the prolapsing leaflet. The remainder underwent mid-
leaflet plication of the prolapsing leaflet. Mean age was 38±10 years and 93% were male.
Median follow-up was 5.5 years (range 0.2 to 9 years). Factors associated with aortic valve
competence and durability were identified by multivariable logistic and hazard function
analyses. 
Results: Early valve competence was more difficult to achieve in patients with large, poor
functioning ventricles (P=0.02). Aortic valve reoperation was necessary in 12 patients that
included three re-repairs and nine aortic valve replacements. Freedom from reoperation
was 95%, 87% and 84% at 1, 5 and 7 years, respectively. The instantaneous risk of
reoperation was highest immediately after operation, and fell rapidly to approximately 2%
per year and less after two years. The only risk factor identified was the presence of
residual aortic regurgitation (trace to mild in 35 cases) on immediate intraoperative post-
repair transesophageal echocardiography. Late aortic regurgitation did not progress
detectably across time (P=0.3). There were no deaths, early or late. 
Conclusion: Bicuspid aortic valve repair for prolapsing leaflet is a safe procedure with good
intermediate-term outcome. However, any residual aortic regurgitation jeopardizes repair
durability and initial repair achievement is more difficult in patients with dilated, poor
functioning ventricles. 
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Introduction
Advantages of aortic valve repair over aortic valve replacement include avoidance of
anticoagulation and prosthetic valve-related complications. Aortic valve repair may be of
particular benefit in young patients, who would be more likely to experience prosthetic
valve-related morbidity over a long life-span.
Although early results of aortic valve repair are good [1, 2], intermediate and long-term
results of aortic valve repair have not been reported. This study was primarily undertaken
to assess the intermediate-term results of aortic valve repair for aortic regurgitation caused
by prolapsing bicuspid aortic valve. A secondary goal was to identify factors associated
with repair failure. 
Materials and methods
Inclusion criteria 
Between November 1988 and January 1997, 435 patients underwent an aortic valve
reparative procedure at The Cleveland Clinic Foundation. This represents 9.7% of the total
aortic valve procedures during the same period. A prolapsing leaflet was present in 136
aortic valves, of which 105 were bicuspid. Ninety-four of these patients were operated upon
by the same surgeon (DMC), which constitutes the patient cohort for this report.
Patient characteristics
Mean age was 38±10 (standard deviation, SD) years (range 16 to 67). Ninety-three percent
was male. In 74 cases (78.7%), the fused leaflets in the bicuspid valves were the right and
left; in 12 patients (12.8%), the fusion was between the right and the non-coronary cusp
and in eight patients (8.5%) between the non-coronary and left cusp. 
Preoperative New York Heart Association (NYHA) functional class was I in 37 (39.2%)
patients, II in 49 (52.1%) patients, III in seven (7.4%) patients and IV in one (1%) patient.
Isolated aortic valve repair was performed in 80 patients. Concomitant procedures
included mitral valve repair in eight patients, coronary artery bypass grafting (CABG) in
two, and ascending aortic aneurysm repair in four. Two patients had previously undergone
coarctation repair, one patient CABG, and one patient congenital aortic balloon
valvuloplasty. 
Preoperative assessment 
All patients had a preoperative Doppler echocardiogram to assess aortic valve pathology,
according to previously described criteria [3-5], to determine left ventricular function [6]
and left ventricular end-diastolic diameter. Preoperative aortic regurgitation distribution
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was 2+ in five patients, 3+ in 28 patients, and 4+ in 61 patients. While 80 patients had no
aortic stenosis on the preoperative echocardiography, 12 patients had mild aortic stenosis
and two moderate. There were only two patients whose left ventricle was not dilated
preoperatively, and the mean left ventricular end-diastolic diameter was 7.0±0.8 cm.
Preoperative left ventricular function was normal in 46 patients, mildly impaired in 30,
moderately impaired in 13, moderately to severely impaired in three, and severely impaired
in two. Coronary catheterization was performed in patients with significant risk factors
or who were older than 45 years of age. 
Repair technique
Initially, full midline sternotomy was used; however, since January 1996 all isolated valve
procedures have been performed via minimally invasive approach (n = 13). After the patient
was placed on cardiopulmonary bypass, the aortic valve repair and any concomitant
procedure was performed under single aortic cross-clamp. The heart was protected by a
variety of techniques throughout the years. The mean aortic cross-clamp and cardio-
pulmonary bypass times were 47±17 minutes and 60±28 minutes respectively.
All patients had a commissuroplasty. In addition, further elimination of the prolapsing
area was by triangular resection and linear closure in 66 (70%) cases or leaflet plication
opposite the raphe in 28 (30%) cases. During the study period, the use of triangular
resection decreased in favor of plication (P<0.0001, Table 1). Other interventions on the
aortic valve are listed in Table 2. Details of the aortic valve repair are described in earlier
publications [7, 8]. 
Table 1: Decrease in prevalence of triangular resection (vs. plication) in recent experience. 
Triangular Resection
Year of Operation N No. %
1988 2 2 100
1989 11 11 100
1990 15 15 100
1991 14 11 79
1992 15 13 87
1993 12 5 42
1994 3 2 67
1995 8 4 50
1996 14 3 21
Total 94 66 70
P
 (logistic trend over time) <0.0001
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Assessment of repair and durability
All patients had an immediate intraoperative post-repair transesophageal echocardiogram
(TEE) to assess the repair. Residual aortic regurgitation of more than 1+ resulted in a
second pump run to improve the repair. The data of the latest available postoperative
transthoracic echocardiogram (TTE) were recorded and was available for 86 patients
(including nine aortic valve replacements during follow-up). Detailed echocardiographic
information was obtained for aortic valve reoperations.
Table 2: Operative techniques for aortic valve repair. 
Level of correction Technique n % of 94
Prolapsing area 1 Triangular resection 66 70
2 Leaflet plication 28 30
Leaflets 1 Closure of incomplete commissure 11 12
2 Leaflet patching 5 5
3 Primary closure of a leaflet perforation 4 4
4 Leaflet debridement 41 44
5 Leaflet shaving 7 7
Commissure 1 Commissurotomy 1 1
2 Commissuroplasty 94 100
Postoperative follow-up
Re-exploration for bleeding was necessary in 5 patients. One patient had a perioperative
myocardial infarction and one patient required prolonged ventilatory support for respiratory
failure. The mean length of postoperative hospital stay was 6.3±1.9 days. 
Follow-up was achieved either by outpatient visit or by telephone interview with the
patient or referring physician and a questionnaire completed with current status, medication,
and information on morbidity and mortality. The data of the most recent echocardiogram
were recorded and detailed information obtained for patients who underwent an aortic valve
reoperation during follow-up.
Mean duration of follow-up was 5.1±2.4 (SD) years (median 5.5 years - range 0.2 to
9 years) and was complete in all patients. There were no deaths, early or late, nor episodes
of thromboembolism or endocarditis. At follow-up, 84 patients were in NYHA functional
class I and 10 patients were in class II (P<0.001 versus preoperative status). 
Reoperations other than aortic valve reoperations were mitral valve repair in one patient,
mitral valve replacement in two, and thoracic aneurysm repair in one. One patient
underwent an aortic valve replacement after a Ross procedure (patient n° 3 of Table 6).
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Data analysis
Durability of repair was assessed primarily by freedom from aortic valve reoperation.
Immediate competence of the aortic valve was assessed by intraoperative TEE after initial
repair and late aortic valve competence by TTE. 
& Overall freedom from aortic valve reoperation
Non-parametric estimates of freedom from reoperation (whether by re-repair or aortic valve
replacement) were obtained by the method of Kaplan and Meier [9]. A parametric method
was used to resolve the number of hazard phases, identify the shape of the hazard function,
and estimate its parameters [10]. 
& Multivariable analysis of aortic reoperation
Variables: Potential risk factors (variables) were organized for entry into the analysis:
demography (age at original aortic repair; sex); aortic valve pathology and function (degree
of aortic valve regurgitation; degree of aortic valve stenosis; leaflet fusion); left ventricular
function (presence of left ventricular dilatation; degree of left ventricular dysfunction
[normal, mild, moderate, moderate-to-severe, and severe]; left ventricular end-diastolic
diameter); aortic valve procedure (triangular resection [n=66]; debridement [n=41]; leaflet
plication [n=28]; resection of raphe [n=15]; leaflet patching [n=5]; commissurotomy [n=1];
leaflet shaving [n=7]; repair of perforation [n=4]); concomitant operations (coronary artery
bypass grafting [n=2]; mitral valve repair [n=8]; repair of ascending aortic aneurysm [n=4]);
and echocardiographic assessment (degree of immediate intraoperative post-repair residual
aortic regurgitation [none, trace, 1+, 2+, 3+, 4+]).
General conduct of the multivariable analyses: Exploratory analysis included correlation
analysis, stratified life table analyses, and decile risk analysis of ordinal and continuous
variables to determine possible transformations of scale. A directed technique of stepwise
entry of variables into the multivariable risk factor model was then used [11]. The P value
criterion for retention of variables in the final model was 0.1. Regression coefficients are
presented plus or minus one standard error. 
Nature and influence of risk factors: Exploration of the influence of risk factors in the
parametric multivariable analysis was performed by constructing a nomogram representing
the solution of the parametric equation for specific values of each factor. 
Immediate assessment of aortic valve competence: Immediate competence of the aortic
valve was assessed by TEE in the operating room. When a second pump run was needed
to achieve satisfactory repair, the grade of aortic regurgitation prior to the second pump
run was used in the analysis. Factors associated with initial grade aortic regurgitation were
identified using both multivariable ordinal logistic regression and binary logistic regression
analyses on both the presence of trace or more regurgitation and more than mild
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regurgitation [12]. The variables were those previously listed except for echocardiographic
assessment. 
Late aortic valve competence: Factors associated with possible progression of aortic
regurgitation were identified by multivariable ordinal logistic regression analysis,
incorporating time of late echocardiographic assessment after operation and variables as
listed above. When aortic valve reoperation was performed, the grade of regurgitation prior
to that reoperation was used in the analysis. 
Results
Immediate assessment of the aortic valve 
During the same time period, no patient of the same surgeon underwent immediate aortic
valve replacement in the same operative session for failure of repair. In eight of the 94
patients a second pump run was required to improve the repair due to residual aortic
regurgitation of more than 1+. In one patient, the suture line after triangular resection was
partially dehisced; two patients had residual central regurgitation which required adjustment
of the commissuroplasty; two patients had their leaflet plication redone; two patients
required a more extensive triangular resection due to residual leaflet prolapse, and one
patient underwent additional leaflet debridement. One patient had 1+ aortic regurgitation
after the first pump run but the jet of regurgitation was considered due to a nodule on one
of the aortic valve leaflets and this was debrided on a second pump run. 
Table 3: Aortic regurgitation as assessed by intraoperative post-repair TEE. 
Grade of After initial repair Including any secondary repairs
regurgitation
n % CL n % CL
      0 55 59 53 – 64 59 63 57 – 68
      Trace 25 27 22 – 32 28 30 25 – 35
      1+ 6 6 4 – 10 7 7 5 – 11
      2+ 6 6 4 – 10 0 0 -
      3+ 2 2 0.7 – 5 0 0 -
      4+ 0 0 - 0 0 -
Total 94 100 94 100
Key: CL, 70% confidence limits
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Degree of aortic competence, immediately after repair and before any second pump run,
are shown in Table 3. One risk factor was identified for immediate intraoperative post-
repair aortic regurgitation exceeding 1+ after the first pump run: increasing left ventricular
dysfunction (correlated with increasing left ventricular size, r=0.3, P=0.02), Table 4.
Triangular resection versus plication was not identified as a risk factor. After any secondary
repair, the degree of aortic regurgitation was 1+ or less in all patients (Table 3). Five (8%)
patients of the 66 who underwent triangular resection versus 3 (11%) of 28 patients who
underwent plication, had more than 1+ aortic regurgitation after the first pump run (P=0.6).
Post-repair, 84 patients had no aortic stenosis and 10 had mild aortic stenosis (P=0.1 from
preoperative); all of them had aortic stenosis preoperatively. 
Table 4: Inadequate aortic valve repair (aortic regurgitation > 1+) after the first pump run (n=8) and its
relation to the degree of preoperative left ventricular dysfunction. 
Degree of left Aortic regurgitation > 1+
ventricular
dysfunction n Number of cases % CL
   None 46 2 4 1 – 10
   Mild 30 1 3 0.4 – 11
   Moderate 13 4 31 16 – 49
   Severe 5 1 20 39 – 53
P
 ( logistic) 0.02; Key: CL, 70% confidence limits
Note: One patient with normal preoperative left ventricular function had a second pump run although residual
aortic regurgitation after the first pump run was 1+ (see text for details). 
Durability of repair
A late follow-up TTE prior to any reoperation (mean interval 3.5 ± 2.4 years after surgery)
was available in 86 patients. Late aortic regurgitation was not demonstrated to progress
with time (P=0.3, Table 5). No risk factors for late aortic regurgitation were identified.
In particular, triangular resection versus plication as technique to eliminate the prolapsing
area did not correlate with late aortic regurgitation (P=0.7). Twenty-two (37%) patients
of 60 who underwent triangular resection had 2+ or more aortic regurgitation at follow-up
versus 10 (38%) of 26 who underwent plication (P=0.7).
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Table 5: Relationship of late aortic valve regurgitation to interval after repair (n=86; data unavailable in
eight patients). In patients who underwent a reoperation, the grade of aortic regurgitation prior to the
reoperation was entered in the table. 
Interval to Grade aortic regurgitation
echocardiographic
follow-up (yrs) N 0 – trace 1+ 2+ 3+ or 4+
N % N % N % N %
      0 - 2 32 16 50 7 22 1 3 8 25
      2 - 4 16 5 31 4 25 6 38 1 6
      4 - 6 23 7 30 4 17 7 30 5 22
      > 6 15 5 33 6 40 3 20 1 7
 
P
 (logistic for trend across time) = 0.3; Key: N = number of patients
During follow-up, 12 patients underwent aortic valve reoperation after the initial valve
repair and are outlined in Table 6. Seven of the 12 reoperations were due to dehiscence
of the suture line at the level of the triangular resection. There were no deaths at
reoperation. 
Table 6: Aortic valve reoperations after repair of bicuspid aortic valve (n=12).
Pt. Operation Technique Post- Pre-reop. Indication Interval Reop.
(year) repair AR AR (months) Procedure
to reop
1 1988 triangular resection trace 3+ Leaflet suture dehiscence 16 Re-repair
2 1989 triangular resection none 3+ AS 57 AVR
3 1989 triangular resection trace 3+ Leaflet suture dehiscence 40 Ross
4 1989 triangular resection trace 3+ Leaflet suture dehiscence 12 Re-repair
5 1990 triangular resection none 3+ Dehiscence at commissure 46 AVR
6 1991 triangular resection trace 3+ Leaflet suture dehiscence 60 Ross
7 1991 triangular resection none 3+ Leaflet suture dehiscence 6 Re-repair
8 1991 triangular resection 1 + 3+ AS 32 Allograft
9 1991 triangular resection 1 + 3+ Leaflet suture dehiscence 15 Allograft
10 1993 triangular resection trace 3+ Leaflet suture dehiscence 6 Ross
11 1993 plication trace 3+ Leaflet suture dehiscence 0. 3 Ross
12 1995 triangular resection none 3+ Dehiscence at commissure 5 Allograft
Key: AR, aortic regurgitation; AS, aortic stenosis; AVR, aortic valve replacement; 
Pt, patient; Pre-reop., pre-reoperative; Reop., reoperative 
After reoperation, the latest echocardiographic findings of aortic regurgitation were
available in 77 of the 85 patients who retained their native aortic valve at the time of
follow-up (this includes three patients who underwent re-repair during follow-up). The
degree of aortic regurgitation was: none in 21 patients, trace in 13, 1+ in 22, 2+ in 16, 3+
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in three and 4+ in two. The five patients with severe aortic regurgitation (3+ or 4+) are
currently asymptomatic with normal left ventricular function and are being followed closely
with regular echocardiogram. 
Freedom from aortic valve reoperation was 95%, 87%, and 84% at 1, 5 and 7 years after
aortic valve repair, respectively (Fig. 1). The instantaneous risk (hazard function) for
reoperation was highest immediately after operation, falling rapidly to approximately 2%
per year or less after two years (Fig. 2). Multivariable hazard function analysis revealed
the presence of residual aortic regurgitation on immediate intraoperative post-repair TEE
as the single risk factor for reoperation (Fig. 3). The methods of repair were not
demonstrably associated with reoperation. 
Figure 1: Freedom from aortic valve reoperation during follow-up. 
Figure 2: Instantaneous risk for aortic valve reoperation during follow-up.
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Figure 3: Freedom from aortic valve reoperation during follow-up according to the amount of aortic
regurgitation on immediate post-repair intraoperative transesophageal echocardiogram.. 
Discussion
Isolated aortic regurgitation is uncommon in the bicuspid aortic valve because most cases
of aortic regurgitation result from endocarditis [13-15]. Apart from this, bicuspid aortic
valve is one of the main causes of isolated aortic regurgitation [4] and, when present, occurs
predominantly at a young age [13] which is reflected in our patient population. Up to 64%
of patients with bicuspid aortic valves have a normal life-span and never develop clinically
significant aortic valve pathology [13-15]. Repair of the insufficient bicuspid aortic valve
aims to return patients into the group with a normal life-span and provide a durable repair.
Aortic regurgitation 
Guidelines to maximize repair durability are necessary to optimize results of repair of
bicuspid prolapsing aortic valve. The result of the repair is assessed in the operating room
by TEE which has proved to be reliable [16]. In this series, residual regurgitation greater
than 1+ resulted in a second pump run in order to improve the repair. However, analysis
indicates that this relatively strict policy should be more strict since patients with any
residual aortic regurgitation after the repair have an increased risk of late repair failure.
In order to reduce the risk of reoperation, the surgeon should aim to eliminate residual
aortic regurgitation at operation; however, this is difficult in patients with large, poor
functioning ventricles.
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The overall 13% prevalence of reoperation at 5 years is higher than reported by Duran et
al [17-19]. However, the maximum follow-up in his series was only 4 years. Carpentier
[20] reported a similar 13% reoperation prevalence but the duration of follow-up is not
quoted in his report. Haydar et al [21] reported a reoperation prevalence of 18% after a
mean follow-up of 2.6 years in a heterogeneous group of patients. In contrast, we
investigated only patients who had a bicuspid valve with leaflet prolapse causing aortic
regurgitation. Patients with rheumatic valve disease were excluded. 
Haydar et al [21] state that the reoperation prevalence is 11% if immediate failures due
to technical errors are excluded. Seven of the 12 reoperations in our series were performed
within 16 months of the initial repair. Whether or not these are all attributable to technical
failures is doubtful. However, the repair is certainly more stable after the first 18 months.
Another consideration was the technique for eliminating the prolapsing area, triangular
resection versus central plication. We gradually changed our technique in favour of
plication of the central area. The advantage of plication is the preservation of the thicker,
central tissue opposite the raphe, which presumably holds the plication suture better. There
is also more coapting surface area of the leaflet when no resection is performed. To date,
we have not demonstrated that this change has improved results. Longer follow-up and
larger numbers should reveal whether plication is more durable than triangular resection.
Another measure of durability is the stability of the repair on follow-up TTE. Carpentier
[20] reported that 15% of patients had moderate aortic regurgitation at echocardiographic
follow-up, while aortic regurgitation of 2+ or greater was present in 26% of all patients
in the present series who still had their native aortic valve. Although all of these patients
are asymptomatic, some of them may require late reoperation. Therefore, close
echocardiographic follow-up is imperative in these patients.
Aortic stenosis 
This study confirms that the repair technique does not create aortic stenosis [1, 2, 7].
However, the technique does not necessarily protect the valve from developing late aortic
stenosis. Two patients with mild aortic stenosis required reoperation predominantly for
combined aortic stenosis and aortic regurgitation (Table 6). It is therefore essential to keep
patients with a history of aortic stenosis in regular echocardiographic follow-up. 
Current strategy
All patients with aortic regurgitation from a prolapsing bicuspid aortic valve who require
intervention are considered candidates for valve repair. Patients with mild aortic stenosis
are also considered candidates for repair; however, the feasibility of repair will have to
be evaluated intraoperatively. 
Morbidity and mortality is minimal. The native aortic valve is preserved and
anticoagulation is unnecessary. 
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Currently, we accept 1+ residual aortic regurgitation as a satisfactory repair. However, since
those patients with any residual aortic regurgitation have an increased risk of reoperation,
the benefits and risks of a second pump-run must be carefully and individually considered.
Plication is the preferred technique for elimination of the prolapsing area. 
Patients should be evaluated by TTE at regular intervals, especially those with residual
aortic regurgitation after initial repair. 
If aortic valve reoperation becomes necessary, the aortic valve can be replaced using
any of the available techniques and the risk of reoperation was very low in this series. 
Limitations of the study 
This is a single-institution, single-surgeon study. While this achieves homogeneity of repair
strategy, it does so at the expense of study size and generalizability. Duration of follow-up
is intermediate-term, which limits long-range inferences. Because many of these patients
were referred for aortic valve repair, only one post-repair echocardiogram is available on
most of the patients. Serial echocardiograms would permit early detection of progressive
aortic regurgitation and identify patients who require reoperation at an earlier stage. As
a substitute for this, we have used a method of longitudinal analysis for aortic competence
assessment that presumes that a group trend, reflecting individual trends, can be detected.
Acknowledgement: The authors wish to thank Karen Mrazeck and Colleen Vahcic for
research assistance. 
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Abstract
Objective: This study was undertaken to evaluate the durability of valve repair in adults
with a tricuspid aortic valve and leaflet prolapse. 
Methods: Thirty-three patients with a tricuspid aortic valve and regurgitation from leaflet
prolapse underwent surgical repair. Mean age was 54±15.9 years. Triangular resection of
the prolapsing leaflet and commissuroplasty were performed in 29 patients (88%). Mean
follow-up was 4.0±2.4 years. 
Results: There were five intraoperative repair failures (15%) requiring immediate aortic
valve replacement during the same operative session. Three patients required reoperation
during follow-up: one patient for suture dehiscence, one patient for 3+ central aortic
regurgitation, and one patient for leaflet tear at a commissure, a rate of 3%/year. Freedom
from aortic valve reoperation at one and five years in successfully repaired patients was
96% and 83%, respectively. There were three late deaths: one sudden and two due to a
cerebral vascular accident.
Conclusion: Successful repair of tricuspid aortic valves is technically challenging, but has
an acceptable midterm outcome when feasible. Regular postoperative assessment of aortic
valve function is however recommended because aortic regurgitation develops in a
substantial proportion of patients by five years.
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Introduction
Literature on aortic valve repair in adults is limited to reports in heterogeneous groups of
patients [1-5]. Patient populations include rheumatic disease, congenital valve disease, and
bicuspid and tricuspid aortic valve pathology. However, results of aortic valve repair may
be influenced by the pathology. We have previously reported our results of bicuspid aortic
valve repair [6]. This study was undertaken to evaluate the durability of repair of tricuspid
aortic valves with leaflet prolapse.
Materials and methods
Inclusion criteria
Between November 1988 and January 1, 1997, 33 patients with a tricuspid aortic valve
and severe aortic regurgitation due to a prolapsing leaflet were considered candidates for
aortic valve repair. Mild aortic stenosis was not an exclusion criterion. Included were five
patients who underwent aortic valve repair and in whom it was immediately apparent that
the repair was inadequate. Consequently, their valves were replaced. These patients were
included in the patient group to portray a realistic picture of the possibility of tricuspid
aortic valve repair for leaflet prolapse. This group of 33 patients represents 0.7% of all
patients having aortic valve procedures during the time period.
Patient characteristics
Mean age was 54±15.9 years (range 21 to 75). Only two patients were female. The
prolapsing leaflet was the right coronary cusp in 27 patients (82%), the non-coronary in
two (6%), and the left in three (9%). One patient (3%) had prolapse of both right and left
coronary cusps. 
Isolated aortic valve repair was performed in 16 patients. Concomitant procedures in
the remaining patients included mitral valve repair in seven (21%), coronary artery bypass
grafting (CABG) in six (18%), mitral valve repair and CABG in two (6%), mitral valve
replacement in one (3%), and ventricular septal defect and patent foramen ovale repair in
one (3%). One patient had previously undergone CABG.
Preoperative New York Heart Association (NHYA) functional class was I in 11 patients
(33%), II in 15 (45%), III in six (18%), and IV in one (3%).
Postoperatively, patients received antiplatelet or Coumadin therapy, as indicated by the
associated procedure or the presence of atrial fibrillation.
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Preoperative assessment
All patients had a preoperative Doppler echocardiogram to assess aortic valve pathology
and measure left ventricular function and left ventricular dimensions [7-10]. Preoperative
aortic regurgitation was 2+ (moderate) in seven patients, 3+ (moderate to severe) in nine
patients, and 4+ (severe) in 17. Mild aortic stenosis was present in seven patients and absent
in the remainder. There was only one patient without left ventricular enlargement
preoperatively, and the mean end-diastolic diameter was 6.9±0.8 cm, ranging from 5.6 to
8.4 cm. The preoperative left ventricular function was normal in 12 patients, mildly
impaired in 13, moderately impaired in seven, and severely impaired in one. Preoperative
heart catheterization was not routinely performed and was indicated when risk factors for
coronary artery disease were present or in patients who were older than 45 years of age.
Repair technique
From 1988 to 1996, the operation was performed via full midline sternotomy; since January
1996, all isolated aortic valve procedures have been performed using minimally invasive
techniques (n=6). All procedures were performed under a single period of aortic cross-
clamping. The mean aortic cross-clamp and cardiopulmonary bypass times were 54±19.5
and 71±28.3 minutes, respectively.
The valve repair usually required application of several techniques to achieve a
competent valve. However, the crucial intervention on the aortic valve was the elimination
of the prolapsing area by a triangular resection in 29 cases and leaflet plication in two
patients. In addition, all but one patient had a commissuroplasty. Other interventions on
the aortic valve included leaflet debridement (n=7), leaflet shaving (n=2), and
commissurotomy (n=1). Further details on our technique of aortic valve repair can be found
in an earlier publication [11].
Assessment of repair success and durability
All patients had an immediate intraoperative post-repair transesophageal echocardiogram
(TEE) to assess success of the repair. Residual aortic regurgitation of more than 1+ (mild)
was followed by a second attempt to improve the repair. The ultimate durability of
successful repair was assessed by the need for reoperation on the aortic valve. In addition,
the latest available transthoracic echocardiogram (TTE) was available in 21 of 24 surviving
patients who retained their native aortic valve at the time of follow-up. Detailed
echocardiographic information was obtained in patients having aortic valve reoperations.
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Postoperative follow-up
Follow-up was achieved either by outpatient visit or by telephone contact with the patient
or referring physician, and a questionnaire on current status, medication, morbidity and
mortality was completed. Mean follow-up was 4.0±2.4 years and ranged from one to eight
years. 
Data analysis
Survival and freedom from aortic valve repair failure (including immediate repair failures)
were estimated nonparametrically by the Kaplan-Meier estimator and parametrically
[12,13].
All parameter estimates (means, proportions, time-related estimates) are accompanied
by the standard deviation or asymmetric 68% confidence limits (CL) equivalent to one
standard deviation (see appendix 1 for potential risk factors).
Results
Operative morbidity and mortality
There were no hospital deaths (0%, CL 0-6%). Postoperative morbidity included respiratory
failure requiring prolonged ventilatory support in one patient, ventricular tachycardia in
one patient, and a superficial wound infection in another patient.
Immediate repair success
The grade of aortic regurgitation as assessed by intraoperative post-repair TEE is shown
in Table 1. After initial repair, five patients had aortic regurgitation that was 2+ or greater.
Each of these patients had a second pump run, resulting in aortic valve replacement in four
and successful re-repair in one. Three of the patients that required aortic valve replacement
had mild aortic stenosis that was treated by leaflet debridement; in each of these cases,
post-repair TEE demonstrated a complex regurgitant jet, and the valve was replaced. One
patient with extremely friable leaflet tissue had aortic valve replacement when it became
apparent that the leaflet would not hold sutures. Thus, in total, five patients had aortic valve
replacement after unsuccessful repair (15%; CL 9-24%, Table 2). 
No patient left the operating room with more than 1+ aortic regurgitation. No important
aortic stenosis was created by the repair technique; 25 patients had no aortic stenosis
postoperatively, and three had mild aortic stenosis as graded by TEE.
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Table 1: Aortic regurgitation assessed by intraoperative post-repair TEE.
 Grade of aortic After 1  aortic valve repair  At end of operation**
regurgitation attempt *
st
N % CL N % CL
       0 12 36 27-47 12 43 32-54
      Trace 11 33 24-44 12 43 32-54
      1+ 4 12 6-21 4 14 7-24
      2+ 4 12 6-21 0 -- --
      3+ 1 3 0.4-10 0 -- --
      4+ 0 0 -- 0 -- --
      Total 32 97 28 100
* Exclusive of 1 patient who underwent aortic valve replacement after attempted repair in a single pump
run, ** Exclusive of 5 aortic valve replacements at initial operation, KEY: TEE, transesophageal
echocardiography; CL, 70% confidence limits
Table 2: Operative details in the 5 patients who underwent immediate aortic valve replacement.
Pt. Year of Age Prolapsing Aortic root AS AR post- Probable
operation cusp repair cause of
failure
1 1988 73 LCC Normal None -- Friable tissue
2 1989 45 RCC Enlarged None 2+ Root dilatation
3 1990 62 LCC Normal Mild 2+ AS
4 1993 52 RCC Normal Mild 2+ AS
5 1995 60 RCC Normal Mild 2-3+ AS
Key: AR, aortic regurgitation; AS, aortic stenosis; AVR, aortic valve replacement; LCC, left coronary cusp;
RCC, right coronary cusp; Pt, patient
Durability of aortic valve repair
Durability of aortic valve repair was assessed by freedom from reoperation. A total of eight
patients required aortic valve replacement. Five of these had aortic valve replacement
during the initial operative session when it became evident that the aortic valve repair had
failed, as described above. In addition, three patients who had a successful repair required
late aortic valve replacement (Table 3). Each of these patients developed aortic
regurgitation, which was the primary indication for reoperation.
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Table 3:
 Reoperation after prolapsing trileaflet aortic valve repair.
Pt. Year of Operative Post-repair Interval Pre-reop Reason Procedure
operation technique AR (mo.) AR
1 1989 Triangular None 18 3+ Central AR; no AVR,
resection structural MVR,
abnormalities TVR
2 1990 Plication Trace 55 3+ Dehiscence of AVR
suture
3 1995 Triangular Trace 11 4+ Tear at Allograft
resection commissure
Key: AR, aortic regurgitation; AVR, aortic valve replacement; Mo., months; MVR, mitral valve replacement;
Pt., patient; Pre-reop, pre-reoperative; TVR, tricuspid valve repair
Figure 1: Freedom from aortic valve repair failure. The five immediate repair failures occurring at the
time of repair are represented by the first circle; the other circles are later reoperations. The vertical bars
are asymmetric confidence limits equivalent to 1 standard error. The solid line and its confidence limits
represent parametric estimates from which the hazard function was determined.
Freedom from reoperation upon the aortic valve including the five immediate failures was
82% (CL, 74 to 88%) at 1 year, and 70% (CL, 59 to 79%) at 5 years postoperatively
(Fig.1). Freedom from reoperation upon the aortic valve in patients with successful repair
(n=28) was 96% (CL, 91 to 99%) at 1 year and 83% (CL, 70 to 91%) at 5 years
postoperatively. After the early failures, the constant hazard for reoperation was estimated
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to be 3.0%/year (CL, 1.7-5.4%/year). The number of events precluded multivariable
analysis. Late transthoracic echocardiograms were available in 21 of 24 patients who
retained their native aortic valve at the time of follow-up. The average echocardiographic
follow-up was 2.6±1.9 years. Aortic regurgitation was 0 to trace in four patients, 1+ in 10,
2+ in three, and 3+ in four.
Late morbidity and mortality
Follow-up morbidity included two transient ischemic attacks (TIA). One occurred 1.5 years
postoperatively in a patient who had a 60 to 80% left internal carotid artery stenosis. The
second TIA occurred six years postoperatively in a patient who was in atrial fibrillation.
There were three late deaths. One was a sudden death in a 60-year-old man and occurred
1.8 years postoperatively. The patient had undergone coronary artery bypass grafting at
the time of the valve repair. The two other deaths occurred in a 73-year-old woman and
a 62-year-old man after cerebral vascular accidents. Neither of these patients had a
concomitant procedure with the initial aortic valve repair, but both had an immediate aortic
valve replacement because of inadequate repair.
The NYHA functional class in the 30 survivors at follow-up was I in 27 patients and
II in three patients.
There were no reoperations other than aortic valve reoperation and there were no deaths
at reoperation.
Discussion
The etiology of leaflet prolapse in adult patients with tricuspid aortic valve structure is
unclear. There is a preponderance of right coronary cusp prolapse, as this was the pathology
in 82% of this series. This may be explained in part by the variation in size and dimension
of the different aortic valve leaflets [14-16]. The non-coronary cusp tends to be the largest
of the three leaflets and the right cusp the smallest. In addition, Kunzelman et al.[16]
reported that the right coronary cusp tends to have a shorter height than the left and non-
coronary cusp (1.33 cm vs. 1.39 and 1.37 cm, respectively). Kunzelman also found that
the length of the free margin of the right cusp is greater than that of the other two cusps
(3.3 cm vs. 3.15 and 3.27 cm, respectively). It is conceivable that the reduced height and
longer free margin of the right coronary cusp predispose to prolapse. This mechanism,
however, is entirely speculative. 
Another possible explanation for aortic regurgitation caused by prolapse of the right
coronary cusp may be found in the association between ventricular septal defects (VSD)
and aortic valve prolapse. It is well known that a VSD can cause aortic valve prolapse and
aortic regurgitation; prolapse most commonly involves the right coronary cusp [17,18].
However, such findings are uncommon in adults. In the current series, only 1 patient had
a VSD, and this patient did have prolapse of the right coronary cusp. Up to 80% of VSDs
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close spontaneously [19]. While it is conceivable that other patients in this series had VSDs
that closed spontaneously, this mechanism is also speculative.
The results reported herein support the notion that repair of a tricuspid aortic valve
presents a greater challenge than repair of a bicuspid aortic valve. In the current series, five
patients had repair failure that was apparent immediately in the operating room; we did
not observe such early repair failures in patients with bicuspid aortic valves [6]. There are
several reasons that prolapse of a bicuspid aortic valve is easier to correct. The thicker
tissue of a bicuspid aortic valve provides a stronger suture line after a triangular resection
or plication of a prolapsing leaflet. In contrast, most of the leaflets in patients with tricuspid
valves were quite fragile and more difficult to handle surgically. Of more importance, the
bicuspid aortic valve with prolapse provides an internal reference point. One of the two
leaflets prolapses while the shorter leaflet provides a reference to the surgeon to dictate
the dimensions of the triangular resection or plication necessary to result in even coaptation
and valve competence. In approaching the tricuspid aortic valve, it is much more difficult
to judge the degree of prolapse present and correspondingly more difficult to resect the
correct amount of tissue. The commissuroplasty technique provides the surgeon some
margin for error by increasing leaflet coaptation. 
The presence of mild-to-moderate aortic stenosis complicates repair of the tricuspid
aortic valve with regurgitation caused by prolapse. Previous studies demonstrate that mild-
to-moderate aortic stenosis does not reduce the ability to repair a bicuspid aortic valve [6].
However, in the current series of patients with tricuspid aortic valves, three of seven
patients with mild preoperative aortic stenosis had unsuccessful aortic valve repair,
necessitating aortic valve replacement for residual aortic regurgitation. Given these results,
repair of the tricuspid aortic valve with leaflet prolapse should be undertaken with caution
in patients with any degree of aortic stenosis. 
Successful repair of the tricuspid aortic valve with prolapse results in acceptable
intermediate-term durability. The 1- and 5-year freedoms from reoperation after successful
valve repair in this series were 96% and 83%. This compares favorably to the 95% and
87% 1- and 5-year freedoms from reoperation in patients having repair of bicuspid aortic
valves [6]. After repair of bicuspid valves, the risk of reoperation gradually fell over time,
from 3.2%/year at 1 year to 2.6%/year at 5 years. The number of reoperations after tricuspid
aortic valve repair was too few to detect anything other than a constant risk. At late follow-
up in the current series, three patients had 2+ aortic regurgitation and four had 3+ aortic
regurgitation. These patients are currently asymptomatic. However, reoperation may
become necessary in the future. 
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Limitations
This report describes an experience with 33 adults undergoing aortic valve repair for aortic
regurgitation caused by leaflet prolapse in a tricuspid valve. The numbers of patients and
events are too small to perform a multivariable analysis to determine risk factors for repair
failure. In addition, systematic serial echocardiographic follow-up was not available. This
report contains midterm follow-up. Continued follow-up will be necessary to determine
the long-term durability of aortic valve repair in patients with tricuspid valves and leaflet
prolapse. 
Conclusions
Repair of a tricuspid aortic valve with leaflet prolapse is technically challenging and carries
an immediate failure rate higher than that observed in patients with bicuspid aortic valves.
In the event of unsuccessful repair (aortic regurgitation that is 2+ or greater), we
recommend aortic valve replacement at the same sitting. After successful repair, patients
require continued follow-up by echocardiography at regular intervals to assess aortic valve
function.
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Appendix 1.
 Potential Risk Factors (Variables)
Demography
Age at original aortic repair
Sex
Aortic valve pathology and function
Degree of aortic valve regurgitation
Degree of aortic valve stenosis
Leaflet prolapse
Left ventricular function
Presence of left ventricular dilatation
Degree of left ventricular dysfunction (normal, mild, moderate, moderate-to-severe, severe)
Left ventricular end-diastolic diameter
Aortic valve procedure
Debridement
Triangular resection
Commissurotomy
Leaflet plication
Leaflet shaving
Commissuroplasty
Concomitant operations
CABG
Mitral valve repair
Mitral valve repair and CABG
Mitral valve replacement
Ventricular septal defect and patent foramen ovale repair
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Abstract
Objective: To determine the durability of aortic valve preservation and root reconstruction
in Type A aortic dissection with involvement of the aortic root. 
Methods: From November 1976 to February 1999, 246 patients underwent surgical
treatment for acute Type A aortic dissection at our institution. In 121 patients (49%), all
with acute Type A dissection and aortic root involvement, the aortic valve was preserved
and one or more of the sinuses of Valsalva were reconstructed. Mean age of this group
was 59±11 years and 70 (58%) were male. Thirty patients (25%) were operated in
cardiogenic shock. Criteria for aortic root reconstruction were technical feasibility and
surgeons preference. Techniques used for reconstruction were valve resuspension in all
patients and additional reinforcement of the aortic root with Teflon® felt (n=21), GRF-
glue® (n=103) or fibrinous glue (n=5). Mean follow-up was 43.5±46 months. 
Results: The operative mortality was 21.5% (n=26). Actuarial survival was 72±4%, 64±5%
and 53±6% at 1, 5 and 10 years respectively. Median aortic regurgitation in patients with
retained native aortic valve at follow-up was 1 +. All root reoperations included aortic valve
replacement (n=12). Freedom from aortic root reoperation was 95±2% at 1 year, 89±4%
at 5 years and 69±9% at 10 years. The incidence of aortic root reoperation was 23%, 11%
and 40% respectively when Teflon® felt, GRF-glue® or fibrinous glue were used for root
reconstruction. Multivariate Cox-proportional hazard analysis revealed the use of fibrinous
glue (RR=8.7; p=0.03) as wel as the presence of an aortic valve annulus > 27 mm (RR=4.2;
p=0.04) as independent risk factors for aortic root reoperation. 
Conclusions: Aortic valve preservation in acute Type A dissection provides relatively
durable results. The use of fibrinous glue for root reconstruction seems to compromise the
long-term durability of the repair when compared with Teflon® felt and GRF-glue®. A
dilated aortic annulus requires a more extensive root procedure. 
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Introduction
Acute Type A aortic dissection according to the Stanford classification [1] involves, per
definition, the ascending aorta. The degree of involvement of the ascending aorta however,
may vary from a discrete intramural hematoma to a totally disrupted aortic wall architecture
including the aortic root. This usually causes severe aortic regurgitation. While surgical
treatment in the former can consist of a short segment replacement of the ascending aorta,
surgical options in the latter need to restore a functional aortic root. This can be obtained
by the Bentall procedure [2]. Since Type A dissection does not affect the aortic valve
annulus neither the valve leaflets, efforts have been made, in individuals without preexisting
aortic valve pathology, to reconstruct in some way the sinuses of Valsalva and resuspend
the aortic valve commissures [3-6]. This aims to restore the geometry of the aortic root
and subsequently aortic valve competence. Reported durability of these different techniques
however is not uniformly good [7] and follow-up is mostly short. The present study focuses
on the durability of the aortic valve preservation and root reconstructive technique in
patients who underwent surgical treatment for an acute Type A aortic dissection with
involvement of the aortic root. The second objective of the study was to determine risk
factors for aortic root reoperation. 
Materials and methods
Inclusion criteria 
From November 1976 to February 1999, 246 consecutive patients underwent surgical
treatment for acute Type A aortic dissection according to the Stanford classification [1].
The dissection was considered acute if the operation was performed within 14 days after
the onset of symptoms. In addition, eligibility for this study required involvement of the
aortic root by the dissection with subsequent surgical reconstruction of one or more of the
sinuses of Valsalva and preservation of the aortic valve. Patients who received a
supracoronary ascending aortic replacement without root reconstruction were excluded
from this analysis as well as patients undergoing a David procedure [8]. Following these
criteria, 121 patients (49%) were included in the study. 
Table 1: Number of patients operated per year throughout the study period (n=121). 
Year 76 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99
N 1 2 2 2 2 1 3 4 3 11 11 13 10 9 7 14 17 7 2
N: number of patients
Chapter 4
60
Patient characteristics
Mean age was 59±11 years (range 24 to 81) and 58% (n=70) were male. Two patients
previously underwent coronary artery bypass grafting (CABG) and another patient
previously had a descending thoracic aorta replacement for a ruptured Type B aortic
dissection. Marfan’s syndrome was present in two patients. The patient distribution per
year is mentioned in Table 1. One fourth of the patients (n=30) were operated in
cardiogenic shock. Preoperative neurological deficit was diagnosed in 19 patients (Table 2).
However, this was transient and fully recovered at the time of surgery in 10 patients.
Associated procedures included partial or total arch replacement in 18 patients, CABG in
four patients and exploratory laparotomy in another four patients. 
Postoperatively patients were anticoagulated with coumadin for three months and were
then switched to antiplatelet therapy unless they were in atrial fibrillation. 
Table 2: Preoperative neurological deficit (n=19). 
Type of deficit Total N Transient N
Paraparesis 2 0
Hemiparesis 11 6
Monoparesis 3 3
Visual disturbance 1 1
Hemiplegia 1 0
Dysphasia 1 0
Total 19 10
N: number of patients
Surgical technique
The technique changed somewhat over the years since a total of 11 surgeons operated on
the patients included in this series. Usually the procedure started with a median sternotomy,
followed by cannulation through the femoral artery and right atrial appendage. A left
ventricular decompression line was inserted through the right superior pulmonary vein.
In cases of hemodynamic instability or resuscitation, extracorporeal circulation (ECC) was
usually initiated by arterial and venous cannulation in the groin using a long venous
cannula, after which median sternotomy was performed. 
Once the patient was on ECC, systemic cooling was initiated. In the early experience,
the distal ascending aorta was clamped at 25-28°C or earlier if ventricular fibrillation
occurred. The proximal aorta was then opened to locate the intimal tear. If the intimal tear
extended into the clamped area, the patient was cooled till a nasopharyngeal temperature
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of 16°Celsius or, since 1982, until the electro-encephalogram became iso-electric. The
proximal reconstruction (see further) was performed during this cooling episode. The arch
was then exposed under deep hypothermic circulatory arrest (DHCA) and partially or
totally replaced if necessary. If it was unnecessary to replace the arch, an open distal aorto-
prosthesis anastomosis was performed and ECC was reinstituted. 
If the intimal tear did not extend into the clamped aortic area, the reconstruction of the
dissected portion was performed under aortic cross-clamping. 
Since 1990 on, antegrade selective cerebral perfusion (ASCP) has progressively been
introduced in our institution. The technique has previously been reported [9] and is
currently our technique of choice for brain protection. Of the 121 patients involved in this
study, a total of 69 had DHCA and 22 patients had ASCP. 
Another modification over the years is to avoid aortic cross-clamping. We currently cool
the patient down till a nasopharyngeal temperature of 25°C at which the ECC is
discontinued. We then install the ASCP and subsequently protect the heart by cold
cristalloid antegrade cardioplegia which is administered directly into the coronary ostia.
The eventual arch procedure and distal ascending aortic anastomosis are performed under
total circulatory arrest. Once this is completed, ASCP is stopped and antegrade perfusion
is resumed through a side arm of the prosthesis. The prosthesis is then de-aired and
clamped. The proximal ascending aortic procedure is performed during the subsequent
rewarming. 
All the patients included in this study had a reconstruction of one or more of the sinuses
of Valsalva which were affected by the dissection. The decision to perform a root
reconstruction rather than a Bentall procedure was taken intra-operatively by the surgeon
and dependant upon his preference and estimation of the feasibility. The aortic root was
reconstructed with either Teflon® (C.R. Bard, Tempe, AZ, USA) felt (n=21), gelatine-
resorcinol-formaldehyde-glue® (GRF-glue®, Fii, Saint-Just-Malmont, France) (n=103),
or fibrinous glue (Tissu-col®, Immuno AG, Vienna, Austria) (n=5). The reconstructive
material was put between the dissected aortic layers. The total number of applications
outranges the total number of patients involved in the study as several patients had a
combination of any of the root reconstructive techniques (Table 3). Two patients had a
surprising combination of GRF-glue® and fibrinous glue. This was due to unforeseen lack
of stock which only became apparent during the operation, when additional glue was
required for optimal apposition of the dissected layers. 
The aortic valve was resuspended by a commissuroplasty, using pledgetted U-stitches
in all patients. The ascending aorta was replaced by a prosthesis starting at the level of the
sino-tubular junction, in all but 10 patients who underwent a local repair of the intimal tear.
These patients were operated early in the series and we currently do not perform local
repair any more. 
Mean aortic cross-clamp time, DHCA and ECC were 101±37, 36±18 and 176±61
minutes respectively.
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Table 3: Aortic root reconstructive techniques used in the study group (n=121). 
Technique used N 
GRF-glue® alone 90
Teflon® felt alone 7
Fibrinous glue alone 1
GRF-glue® + Teflon® felt 11
GRF-glue® + fibrinous glue 1
Teflon® felt + fibrinous glue 2
GRF-glue® + Teflon® felt + fibrinous glue 1
Unknown 8
GRF-glue®: gelatine-resorcinol-formaldehyde-glue® ; N : number of patients
Assessment of repair and durability
The initial repair was assessed intra-operatively, at first by the hemodynamic parameters
and from 1988 on also by transoesophageal echocardiography (TEE) whenever available.
This was however not always the case in emergency conditions. 
The repair durability was primarily assessed by the incidence of aortic valve and root
reoperation. All reoperations were analysed and the causes were noted. All other re-
operations were also recorded. Causes of death were also analyzed to detect recurrent aortic
regurgitation as a possible causative factor. 
In addition, the latest available transthoracic echocardiogram (TTE) was used to
determine the degree of aortic regurgitation and the presence of aortic root dilatation. TTE
was available in 56 of 67 patients who retained their native aortic valve at the time of
follow-up. In patients undergoing an aortic valve and root reoperation, the last TTE prior
to the reoperation was used. 
Table 4: Causes of 30 day mortality (n=26). 
Cause of death N
Stroke 13
Heart failure 5
Hemorrhage 5
Sepsis 2
Unknown 1
N: number of patients
Valve repair in aortic dissection
63
Postoperative follow-up
The 30 day mortality was 21.5% (n=26). Ten of these patients were operated in cardiogenic
shock. Causes of death are summarized in Table 4. None of the patients dying of heart
failure had recurrent aortic regurgitation. Six of the 13 neurological deaths occurred in
patients who had a preoperative persisting central neurological deficit and one in a patient
who had preoperatively a transient neurological deficit. Actuarial survival at 30 days was
78±4%. 
Postoperative complications were frequent: nine patients required temporary dialysis,
23 patients required prolonged (>5 days) mechanical ventilation and 15 patients
experienced a new peri-operative neurological event. In 10 of these, the deficit was central
versus peripheral in five.
Follow-up was achieved either by yearly outpatient visit or by phone and letter to the
patient and his referring physician. A file on current status, medication, morbidity and
mortality was completed per patient. Follow-up was closed June 1  1999 and was 100%st
complete. Mean follow-up was 43±46 months with a maximum of 16 years in two patients.
There were 20 late deaths. The causes are summarized in Table 5. Four of these deaths
occurred after an aortic valve reoperation (see ‘Results’). None of the patients died of
recurrent aortic regurgitation. Actuarial survival was 72±4%, 64±5% and 53±6% at 1.5
and 10 years postoperatively (Fig. 1). 
Table 5: Causes of late death (n=20). 
Cause of late death N
Aortic rupture 5
Sepsis 3
Stroke 3
Heart failure 3
Sudden death 2
COPD 1
Malignancy 1
Unknown 2
N: number of patients; COPD: chronic obstructive pulmonary disease
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Figure 1: Actuarial survival of patients with acute Type A dissection and aortic valve preservation
(including 30 day mortality).
Eight patients with retained native aortic valve experienced a neurological event during
late (>30 days) follow-up: six had a transient ischaemic attack (TIA) and two a stroke. One
patient had two TIA’s; another twice a stroke for a total of 10 postoperative neurological
events. With the exclusion of the preoperative and per-operative neurological events, the
postoperative freedom from thrombo-embolic event rate was 95% at 1 year and 89% at
10 years (Fig. 2). 
Figure 2: Freedom from thrombo-embolic events in patients surviving >30 days (exclusive the preoperative
and peri-operative neurological events). 
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Statistical analysis
The design of the study was retrospective and analysis was performed with the Statistical
Analysis Software (SAS Institute, version 6.12 for Windows, Cary, NC). Data are expressed
as the mean ± the standard deviation. Survival and event-free estimates were determined
by the method of Kaplan-Meier [10] and are expressed as proportion ± the standard error.
Comparison between variables was performed with the chi-square or Fisher exact test when
appropriate. A p-value less then 0.05 was considered statistically significant. Cox
proportional hazard analysis was used to determine risk factors for aortic valve reoperation.
Variables with a p-value < 0.15 on univariate analysis were entered in the multivariate
analysis. 
Results
Aortic root reoperation
Aortic root reoperation occurred in 12 patients at a mean of 4±2.8 years postoperatively.
Details on these patients are summarized in Table 6. Aortic root dilatation with subsequent
aortic regurgitation was the major cause of reoperation, occurring in nine patients. All root
reoperations included aortic valve replacement. Four patients died at reoperation. Freedom
from aortic root reoperation was 95±2%, 89±4% and 69±9% at 1, 5 and 10 years
respectively (Fig. 3).
A total of eight patients had an aortic valve annulus > 27 mm measured intraoperatively
and four of these patients required a reoperation (Table 6). Reoperation occurred in five
of 21 (23%) patients in whom Teflon® was used for reconstruction of the aortic root. With
regard to the use of GRF-glue® and fibrinous glue, reoperation occurred in 11 of 103
patients (11%) and 2 of 5 patients (40%) respectively. Multivariate Cox-proportional hazard
analysis revealed the use of fibrinous glue (RR=8.7; p=0.03) and the presence of an aortic
valve annulus > 27 mm (RR=4.2; p=0.04) as independent risk factors for aortic root
reoperation. The use of Teflon® was correlated with an increased risk for reoperation
(RR=2.8 on univariate analysis and RR=1.5 on multivariate analysis) but this was not
statistically significant (p=0.08 and p=0.5 on uni- and multivariate analysis respectively).
Freedom from aortic root reoperation was significantly worse when one or two of the
independent risk factors were present as was the case in 11 patients; it was 97% at 1 year,
92% at 5 years and 79% at 7 years if risk factors were absent versus 79% at 1 year, 66%
at 5 years and 33% at 7 years when any or both of the risk factors were present (p=0.0001)
(Fig. 4). The curve of the patients with risk factors falls to zero since the patient with the
longest follow-up in this group was reoperated 7.4 years after the initial operation. 
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Table 6: Aortic valve/root reoperations during follow-up. 
Pt Operation Technique annulus Pre-reop Primary indication Interval to Reoperative Outcome
(year) > 27 mm AR for reoperation reop procedure
at in. oper (months)
1 1985 Teflon Yes 4 + Root dilatation 75 Bentall Alive
2 1988 GRF No 2 + False aneurysm; 83 Bentall, CABG Alive
2 VD
3 1990 GRF Yes 4 + Root dilatation 11 Bentall Reop death
4 1990 Teflon + GRF No 3 + Root dilatation 70 Bentall, arch, ET Alive
5 1990 GRF Yes 2 + Root dilatation; 66 Bentall, arch, ET, Alive
2 VD CABG
6 1991 GRF No 4 + Root dilatation 41 AVR, asc, arch, ET Alive
7 1991 Teflon + GRF Yes 4 + Root dilatation; 22 Bentall, arch, ET, Alive
+ Fibrinous glue 3 VD CABG
8 1992 Teflon + GRF No 4 + Root dilatation; 67 Bentall, CABG Alive
2 VD
9 1992 GRF No 3 + Root dilatation; 39 Bentall, arch, ET, Alive
2 VD; MR CABG, MVR
10 1992 GRF No 4 + Dehiscence at 2 AVR Reop death
commissure
11 1992 Teflon + GRF No 2 + Root dilatation 12 AVR, asc Reop death
12 1997 GRF + Fibrinous No 2 + Graft infection 7 AVR homograft, Reop death
glue omentoplasty
AR: aortic regurgitation; arch: aortic arch replacement; asc: ascending aortic replacement; AVR: aortic valve
replacement; CABG: coronary artery bypass grafting; ET: elephant trunk; GRF-glue®: gelatine-resorcinol-
formaldehyde-glue®; in. oper: initial operation; MR: mitral regurgitation; MVR: mitral valve replacement;
Pre-reop: pre-reoperative; Pt: patient; reop: reoperation; VD: vessel disease
Figure 3: Freedom from aortic root reoperation in patients surviving > 30 days. 
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Figure 4: Freedom from aortic root reoperation (>30 days) according to the presence of risk factors
-.- with risk factors; -- without risk factors. 
Other reoperations 
Twelve additional aortic reoperations were performed during follow-up. These included
three false aneurysms at the distal prosthesis-aortic arch anastomosis, one more prosthesis
infection, two descending aortic aneurysm replacements, two thoracoabdominal aortic
aneurysm replacements, three abdominal aortic aneurysm replacements and one iliac artery
reconstruction. There were no deaths at these additional reoperations. Freedom from any
aortic reoperation was 92±3%, 81±5% and 54±9% at 1, 5 and 10 years postoperatively
(Fig. 5).
Figure 5: Freedom from any aortic reoperation in patients surviving >30 days. 
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Assessment of repair durability
As stated earlier, none of the patients who died of heart failure (five operative deaths and
three late deaths), had recurrent aortic regurgitation. 
At follow-up, 67 patients of 75 survivors had retained their native aortic valve. A TTE
was available in 56 of these patients. As indicated in Table 7, the majority of the patients
had no or 1+ aortic regurgitation. Median degree of aortic regurgitation was 1+. Twelve
patients had 2+ and 2 patients had 3+ aortic regurgitation. They are currently asymptomatic
but carefully followed at regular intervals. 
Details concerning the aortic root dimensions at the level of the sinuses of Valsalva,
measured in the same patient cohort at follow-up, are given in Table 8. Ten patients had
an aortic root measuring over 40 mm of whom 2 had a diameter exceeding 50 mm, a limit
that is currently considered being an operative indication [8]. 
Table 7: Results of the follow-up TTE with regard to the presence of aortic regurgitation (n=56 of 67
surviving patients with retained native aortic valve). 
Degree of aortic regurgitation N
     0 19
     1 + 23
     2 + 12
     3 + 2
N: number of patients; TTE: transthoracic echocardiogram
Table 8: Follow-up TTE measurements of the aortic root at the level of the Sinuses of Valsalva (n=56 of
67 surviving patients with retained native aortic valve). 
Diameter in mm N
     35 or less 37
     36 – 40 9
     41 - 45 7
     46 - 50 1
     > 50 2
mm: millimeter; N: number of patients; TTE: transthoracic echocardiogram.
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Comment
Operative mortality
Although the outcome of the surgical management of Type A dissection has considerably
improved over the years [11-12], operative mortality is still substantial. Reported operative
mortality in literature is as low as 6 [5-6] to 8% [13] but is usually between 20 and 30%
[3-4, 7, 12, 14-17]. Our operative mortality was 21.5% (n=26) which is comparable with
these reports. One of the contributing factors to this high operative mortality is undoubtedly
the high proportion of (referred) patients operated in cardiogenic shock (25%). Ten of 30
patients operated in cardiogenic shock died. Major efforts are constantly made to organise
prompt referral of patients diagnosed with Type A dissection in order to decrease the
incidence of preoperative cardiogenic shock. We hope this will contribute to decrease
operative mortality. 
Durability of the root repair
Durability was assessed by the incidence of aortic root reoperation and by follow-up TTE.
Advantages of preservation of the native aortic valve are avoidance of a valve substitute
with its possible adverse effects but also avoidance of a permanent need of anticoagulation
in mechanical valve replacement. This need of anticoagulation will impair the spontaneous
thrombosis in the false lumen and persistent perfusion of the false lumen will lead to
aneurysm formation which has been associated with decreased late survival [11]. The
advantages of valve preservation have to be balanced against the risk of reoperation during
follow-up. Freedom from aortic valve reoperation at 10 years has been reported to be as
high as 95% [17] when valve preservation was performed. However, other reports mention
80% freedom from aortic valve reoperation at 10 years [4, 18]. Freedom from aortic
valve/root reoperation at 10 years in the present series was 69%. This is somewhat lower
than the previously mentioned reports. 
Table 6 indicates that the use of GRF-glue® did not prevent aortic root dilatation in some
instances, contrary to a previous report [6]. In addition, follow-up TTE revealed two
patients with 3 + aortic regurgitation and 10 patients with an aortic root diameter > 40 mm.
It seems undoubtful that some of these patients will need reoperation in the future. Further
follow-up of this patient cohort seems therefore mandatory. 
Risk factors for root reoperation
Multivariate Cox-proportional hazard analysis revealed the use of fibrinous glue and the
presence of an aortic valve annulus > 27 mm as independent risk factors for aortic root
reoperation. This negative impact of fibrinous glue is in sharp contrast with the previously
reported results with fibrinous glue by Séguin et al. [5]. This paper reports on the use of
fibrinous glue in 15 patients with Type A dissection. There was one non-valve-related
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operative death and at a mean follow-up of 2.3 years, the mean aortic regurgitation grade
was 0.3. No reoperations were reported.
Most authors currently agree that Marfans’ disease and annuloaortic ectasia represent
a contra-indication to root preservation during surgery for Type A dissection [3-4, 6, 14,
16, 18]. These patients should undergo a Bentall procedure [2] or alternatively the
procedure described by David et al. [8]. Four of the reoperations in the current series
occurred in patients having an aortic annulus > 27 mm measured peroperatively. All of
these initial operations were performed earlier in the series. In retrospect these patients
should not have undergone a root reconstructive procedure which would have decreased
the reoperation incidence. 
Although not statistically significant, the present series demonstrates a trend towards
improved durability in patients treated with GRF-glue® versus Teflon®. The reoperation
rate in patients treated with GRF-glue® was 11% versus 23% when Teflon® was used.
Equally good results with GRF-glue® have been reported by others, either reporting on
a single experience with GRF-glue® [3, 6, 14] or in comparison with Teflon® [19]. The
use of GRF-glue® for the reapproximation of the dissected aortic layers decreases the
incidence of reoperations as wel as the persistence of false lumina thus increasing the event-
free survival. However, in the paper by Pessotto et al. [16], the use of GRF-glue® had no
impact on the incidence of reoperation which increased with increasing preoperative aortic
regurgitation. Another concern with regards to the use of GRF-glue® is the recent paper
by Fukunaga et al. [7]. In a series of 148 patients in whom GRF-glue® was used to
reinforce the dissected layers, reoperations were necessary in 20 patients. In nine of these
patients, complications necessitating reoperation occurred in aortic segments that underwent
reconstruction with GRF-glue® at the first intervention. Root redissection was present in
seven patients and another patient presented with a rupture near the distal graft-aorta
anastomosis. Macroscopically, the areas looked necrotic but histologic examination in two
patients revealed media degeneration rather than necrosis. We had no similar experience
as reported in this paper. In particular, we haven’t seen redissection occurring in areas
treated with GRF-glue®. However, this paper raises an important concern which needs
further follow-up. In particular, the formaldehyde component, when excessively used,
seems to cause tissue necrosis [7]. 
Limitations of the study
The current series is a retrospective review covering a long time interval. Accordingly,
many surgeons have operated on the patients included in this study. Although every surgeon
might have his personal approach, the technique used to reconstruct the aortic root was
relatively uniform, with the exception of the use of Teflon®, GRF-glue® or fibrinous glue
to approximate the dissected layers. Besides, the decision to perform a root reconstruction
was taken intra-operatively and entirely dependant on the surgeons preference and
estimation of the feasibility. This is of course very subjective and might have contributed
Valve repair in aortic dissection
71
to a selection bias of patients undergoing root reconstruction. In addition, the individual
choice of the product used for root reconstruction resulted in different sample sizes and
combination of different products. This bias however should have been taken care of by
the statistical analysis. 
Another limitation of the study is the absence of a grading system reflecting to what
extent the aortic root was affected by the dissection. We initially aimed to do so but given
the retrospective nature of the study, many operative reports did not mention to what extent
the aortic root was affected and we abandoned this idea. We are therefore unable to
determine whether reoperations occurred in the more heavily affected aortic root. It is
however our current strategy to reconstruct the aortic root only when one sinus is affected
completely or two sinuses partially. If the dissection involves more than one sinus of
Valsalva, we currently favor the reimplantation technique described by David [8]. 
Conclusion
Aortic valve preservation and root reconstruction in patients undergoing surgery for acute
Type A aortic dissection with involvement of the aortic root, provides relatively durable
results. Freedom from aortic root reoperation is 69% at 10 years. 
The use of fibrinous glue seems to compromise the durability of the repair and there
is a trend towards enhanced durability whenever GRF-glue® is used versus Teflon®. 
We believe that an aortic valve reimplantation procedure according to David or a Bentall
procedure is more appropriate in patients with an aortic annulus >27 mm. 
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CHAPTER 5
Reimplantation of the aortic valve:
first experiences in 13 patients
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Abstract
Objective: To report our initial experience with the reimplantation technique of the aortic
valve.
Methods: From January 1  1998 till January 31  2000, 13 patients were operated on. Meanst st
age was 52.2±11 years. Median preoperative NYHA functional class was 2 and median
preoperative degree of aortic regurgitation was 3. Surgical indications were initially limited
to aneurysmal disease of the aortic root (n=6) and ascending aorta (n=4), all complicated
by aortic regurgitation. Later on, we also applied the technique in Type A aortic dissection
(n=3). 
Results: Mean cardiac arrest time and cardiopulmonary bypass time were 184±40 and
254±74 minutes. The primary etiology on histopathological examination was medial
necrosis in 5 patients and degenerative disease in the remaining. There was no early neither
late mortality and none of the patients was reoperated upon the aortic root. Follow-up was
complete at a mean of 12.3±8 months. Median aortic regurgitation at follow-up was 0.5
(p=0.0001 versus preoperative) and median NYHA functional class at follow-up was 1
(p=0.02 versus preoperative). 
Conclusions: Our initial experience with the reimplantation technique is promising. The
aortic root and ascending aorta are reconstructed and residual aortic regurgitation is
minimal. Further experience and follow-up remain necessary to evaluate this technique
on the long-term. 
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Inleiding
De aortawortel bestaat uit de aortaklep met net daarboven de drie sinussen van Valsalva
welke apicaal begrensd worden door de sinotubulaire junctie die de overgang vormt naar
de eigenlijke (tubulaire) aorta ascendens. De normale aortaklepfunktie is een complexe
interactie van deze 3 onderdelen en veronderstelt een appositie van de drie klepblaadjes
tijdens diastole zodat er geen lekkage kan optreden van de aorta naar de linker ventrikel.
Bij patiënten met een aneurysma van de aortawortel (Fig. 1) ontstaat er vaak een secundaire
(centrale) aortaklep lekkage omdat er door het aneurysma een dilatatie optreedt van de
sinotubulaire junctie waardoor er tijdens diastole geen goede coaptatie van de klepblaadjes
meer kan plaatsvinden. Tot nog toe werden deze patiënten behandeld met een volledige
aortawortel vervanging, de zogenaamde ‘Bentall’ operatie [1]. Deze ingreep omvat een
aortaklepvervanging met een conduit bestaande uit een buisprothese waarin de klepprothese
(meestal mechanisch) reeds is ingehecht. Dit geheel vervangt aldus de aortaklep, de
sinussen van Valsalva, de sinotubulaire junctie en een variabele lengte van de aorta
ascendens. De coronair arteriën worden elk afzonderlijk gereimplanteerd in de buisprothese.
Figuur 1: Schematische voorstelling van een aneurysmatisch verwijde aortawortel. AA: aorta ascendens;
AC : arcus aortae ; AD : aorta descendens ; LCA: linker coronair arterie; RCA: rechter coronair arterie;
ST: sino-tubulaire junctie. 
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Een lange termijn onderzoek bij patiënten die een Bentall operatie hebben ondergaan leert
echter dat er een niet te verwaarlozen incidentie complicaties optreedt waaronder het risico
op reoperatie (1.6%/patiënt-jaar), trombo-embolieën (0.4%/patiënt-jaar) en anticoagulantia
gerelateerde bloedingsproblemen (1.2%/patiënt-jaar)[2]. Deze laatste twee complicaties
zijn inherent aan het levenslang verplicht gebruik van bloedverdunnende medicijnen bij
patiënten die een mechanische klepvervanging ondergingen. 
Anderzijds is het vaak zo dat bij patiënten met een aneurysma van de aortawortel de
eigenlijke aortaklep macroscopisch niet is aangetast en een normale structuur vertoont. Dit
betekent dat de aortaklep lekkage bij deze patiënten kan verdwijnen door de dilatatie van
de sinotubulaire junctie op te heffen. 
Daarom werd door Tirone David een operatietechniek ontwikkeld waarbij de natieve
aortaklep gereïmplanteerd wordt in een buisprothese waarmee de sinussen van Valsalva
en de proximale aorta ascendens vervangen worden [3-4]. In ons ziekenhuis werd deze
techniek in 1998 voor het eerst toegepast. In dit artikel beschrijven wij de opgedane
ervaringen.
Patiënten
Van 1 januari 1998 tot 31 januari 2000 werden 13 patiënten geopereerd. Dit betrof 9% van
alle operaties aan de aortawortel in die periode. Kandidaten voor deze techniek werden
geselecteerd op grond van een preoperatief echocardiografisch onderzoek. Hierbij was er
een aneurysma van de aortawortel aanwezig en/of een ernstige aortaklep lekkage op basis
van een dilatatie van de sinotubulaire junctie bij een morfologisch normale drieslippige
aortaklep. Aortaklepstenose of verkalkingen in de aortaklepring waren een exclusie
criterium maar een verwijde annulus niet. De definitieve beslissing voor het uitvoeren van
de techniek werd peroperatief genomen. De geopereerde patiënten waren 10 mannen en
drie vrouwen met een gemiddelde leeftijd van 52.2±11 jaar. De mediane preoperatieve
NYHA functionele klasse bedroeg 2 (het betreft hier een schaal van 1 tot 4 waarbij 1 een
normale functionele toestand betekent en 4 kortademigheid in rust). Het betrof in alle
gevallen een eerste hartoperatie. Initieel werden alleen patiënten met een aneurysma van
de aortawortel (n=6) of de aorta ascendens (n=4) geaccepteerd voor deze ingreep.
Naderhand werd de techniek ook toegepast bij patiënten met een Type A dissectie
(=dissectie waarbij de aorta ascendens is betrokken) waarbij de dissectie doorliep tot in
de sinussen van Valsalva met een volledige verstoring van de geometrie van de aortawortel
(n=3). Het merendeel van de patiënten had preoperatief een ernstige aortaklep lekkage als
gevolg van de pathologie van de aortawortel. De mediane preoperatieve aortaklep lekkage
bedroeg 3 (=schaal van 0 tot 4 waarbij graad 4 massale aortaklep lekkage betekent).
Behoudens de drie patiënten met een Type A dissectie was de ingreep steeds electief. 
De comorbiditeit bestond bij vijf patiënten uit arteriële hypertensie, twee patiënten
hadden coronarialijden en een andere patiënt had chronisch obstructief longlijden. Bij zes
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patiënten waren reeds familieleden geopereerd aan het hart of de aorta. Geen enkele patiënt
had de kenmerken van het syndroom van Marfan. 
 
Operatietechniek
De patiënt wordt op de gebruikelijke manier aangesloten aan de hartlong machine. In eerste
instantie wordt met behulp van een aparte prothese de distale aorta ascendens, indien nodig,
vervangen (Fig. 2). 
Figuur 2: De distale anastomose is voltooid; de prothese is afgeklemd en lichaamsperfusie gebeurt via
een zijarm op de prothese.
Nu wordt de aortawand ter hoogte van de drie sinussen van Valsalva uitgesneden en worden
de twee coronaire ostia geïsoleerd voor latere reïmplantatie. Vervolgens wordt de proximale
hechtlijn gelegd door afzonderlijke draden polypropylene 4/0 als U-hechtingen net onder
de aortaklepblaadjes door de aortaklepannulus van binnen naar buiten aan te brengen,
waarbij zoveel mogelijk een horizontale lijn wordt aangehouden (Fig. 3). Vervolgens
worden deze hechtingen door de prothese gebracht en wordt de prothese ingeknoopt. De
maat van de proximale prothese wordt bepaald door de maximale hoogte van de
klepblaadjes (KB) en wordt als volgt berekend: KB(in mm) x 2/3 x 2 + 5mm = diameter
prothese in mm. De maximale hoogte van de klepblaadjes wordt peroperatief bepaald door
directe meting vanaf de annulus tot de vrije rand.
Chapter 5
78
Figuur 3: Proximale aortawortel reconstructie : de U-hechtingen worden in een horizontaal vlak door
de aortaklepring van binnen naar buiten gebracht en vervolgens door de prothese.
Figuur 4: Eindresultaat nadat de aortaklep in de prothese werd gefixeerd, de coronaire ostia werden
gereimplanteerd en de anastomose tussen de 2 prothesen werd voltooid. De zijarm van de prothese werd
doorgenomen en overhecht. 
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De natieve aortaklep bevindt zich nu centraal in de prothese en wordt hierin gefixeerd: eerst
worden de drie commissuren op de juiste hoogte opgehangen; vervolgens wordt een
doorlopende hechtlijn gemaakt met polypropylene 5/0 tussen de basis van de
oorspronkelijke sinus van Valsalva en de prothese. Daarna worden de coronaire ostia
gereimplanteerd met behulp van een polypropylene draad 6/0. Als laatste anastomose
worden nu de beide prothesen aan elkaar gehecht (Fig. 4). Het vervolg van de procedure
is standaard.
Het resultaat van de plastiek wordt peroperatief beoordeeld door een transoesophagale
echocardiografie en postoperatief door een transthoracale echocardiografie. Postoperatief
worden de patiënten gedurende drie maanden geanticoaguleerd (gezien de aanwezigheid
van kunstmateriaal) of langer indien hiervoor andere indicaties zijn. 
Resultaten
Er traden geen technische problemen op welke een verandering of aanpassing van de
techniek noodzakelijk maakten. Postoperatieve ondersteuning met inotropica was tijdelijk
nodig bij een patiënt. Geassocieerde procedures aan de ‘Davidplastiek’ waren een totale
boog-vervanging bij vier patiënten (waarvan twee met additioneel een elephant trunk
procedure en een met additioneel een proximale aorta descendens vervanging); zes
patiënten kregen een partiele boog vervanging en twee patiënten ondergingen een myocard
revascularisatie. Slechts drie van de 13 patiënten ondergingen geen additionele procedure.
De gemiddelde cardiale ischemie tijd en extracorporele circulatie duur bedroegen
respectievelijk 184±40 en 254±74 minuten. Bij een patiënt diende een dreigende tamponade
ontlast te worden op de eerste postoperatieve dag. Verder waren er geen grote post-
operatieve problemen. Er waren geen perioperatieve neurologische afwijkingen. Er was
geen operatieve (noch laattijdige) sterfte. 
Histologisch onderzoek van de aortawand toonde de aanwezigheid van primaire tunica
media degeneratie bij vijf patiënten. De andere patiënten vertoonden degeneratieve
veranderingen met uiteraard tekenen van aorta dissectie bij drie patiënten.
Er waren geen reoperaties aan de aortawortel maar een patiënte met een mega-aorta
onderging wel een correctie van een thoraco-abdominaal aneurysma, 6 maanden nadat zij
een David plastiek, aangevuld met een totale boog vervanging en een elephant trunk, had
ondergaan. Een andere patiënt onderging 2,5 maand na de initiële operatie, een
subxyphoidale punctie ter ontlasting van een late tamponade. Er waren geen episoden van
endocarditis noch traden er trombo-embolische complicaties op.
Na een gemiddelde follow-up tijd van 12.3±8 maanden was de mediane aortaklep
lekkage 0.5 (p=0.0001 versus preoperatief). De ernst van de preoperatieve aortaklep lekkage
hield geen verband met de ernst van de laattijdige graad van lekkage (p=0.7). De mediane
NYHA functionele klasse bij follow-up was 1 (p=0.02 versus preoperatief). 
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Commentaar
Aortawortel dilatatie is tegenwoordig de meest frequente oorzaak van geïsoleerde aortaklep
lekkage. De prevalentie lijkt bovendien ook toe te nemen, waarschijnlijk door een afname
van de rheumatische klepaandoeningen [5]. Aortawortel dilatatie kan ontstaan op
degeneratieve basis maar kan ook geassocieerd zijn aan het syndroom van Marfan of aan
andere aandoeningen die gepaard gaan met een verzwakte aortawand zoals primaire media
degeneratie of stoornissen van het bindweefsel zoals het Ehlers-Danlos syndroom [6-8].
Deze diversiteit in etiologie is ten dele ook in onze patiënten populatie aanwezig gezien
het histologisch onderzoek degeneratieve veranderingen aantoont bij acht patiënten en een
primaire media degeneratie bij vijf patiënten. Patiënten met een andere bindweefsel
aandoening werden tot nog toe niet voor deze ingreep in aanmerking genomen. 
Daar bij deze aandoeningen de aortaklep annulus alsook de klepblaadjes macroscopisch
normaal zijn en er anderzijds nog geen perfecte klepprothese beschikbaar is op de markt,
lag het voor pioniers als David voor de hand een operatieve techniek te ontwikkelen waarbij
nagenoeg de gehele aortawand ter hoogte van de aortawortel wordt weggenomen en de
natieve aortaklep opnieuw wordt opgehangen in een buisprothese [3]. Deze ‘reïmplantatie’
techniek werd voor het eerst gepubliceerd in 1992 maar betrof toen slechts 10 patiënten.
Eén van de potentiele nadelen welke toen geopperd werden, was het mogelijk ‘slijtage
effekt’ op de klepblaadjes als deze in systole tegen de prothese aan slaan gezien de techniek
alle drie sinussen van Valsalva opheft. Of het opheffen van de sinussen van Valsalva op
zichzelf een nadelig effect zou uitoefenen op de klepfunctie was evenmin bekend. 
Toen ook andere groepen de techniek met mondjesmaat begonnen uit te voeren [9-11]
en in 1997 uitstekende middellange resultaten door David gepubliceerd werden [12]
besloten ook wij deze techniek te gaan uitvoeren. Aanvankelijk beperkten wij ons tot
aneurysmata van de aortawortel en aorta ascendens. Daar deze techniek echter door
nagenoeg iedereen die ze toepast ook aangewend wordt ter behandeling van Type A aorta
dissecties [3, 9-11] en anderzijds de laattijdige resultaten van aortawortel reconstructie bij
Type A dissectie zeker voor verbetering vatbaar zijn [13-14] besloten ook wij deze techniek
voor deze indicatie toe te passen, ten minste in die gevallen waar de dissectie doorloopt
tot in de sinus(sen) van Valsalva. Hierdoor zal ongetwijfeld het aantal indicaties voor deze
techniek toenemen. Bicuspide aortakleppen hebben wij alsnog niet in onze indicatiestelling
opgenomen ofschoon dit door anderen wel gebeurt [15].
Onze eerste ervaringen met deze techniek zijn gunstig. Wel is duidelijk dat deze techniek
enkel is weggelegd voor chirurgen met ruime ervaring in de aortawortel chirurgie; ook zij
ondervinden een zeker leerproces. Dit uit zich ten dele in de relatief lange cardiale ischemie
tijd (184±40 minuten) al wordt deze uiteraard ook bepaald door het relatief hoog aantal
geassocieerde ingrepen in deze patiëntengroep (slechts drie patiënten hadden geen
geassocieerde ingreep en sommigen hadden verscheidene geassocieerde ingrepen). Ondanks
de leercurve kenden wij echter geen technische problemen bij het uitvoeren van de techniek,
met name traden er geen problemen op van valse aneurysmata op de proximale naad of
ontstond er geen myocardischemie door technische problemen met de reïmplantatie van
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de coronair arteriën. De twee patiënten die een myocard revascularisatie ondergingen
hadden preoperatief aangetoonde letsels.
Morbiditeit was gering en mortaliteit afwezig. Follow-up echocardiografie toont dat de
techniek de aortawortel dilatatie corrigeert en de aortaklep lekkage nagenoeg opheft. Het
blijft echter belangrijk de patiënten op regelmatige basis te blijven controleren omdat twee
gevallen van recidiverende aortaklep lekkage werden gepubliceerd [16-17]. Daar tegenover
staan echter de uitstekende middellange termijn resultaten van David waarbij slechts 3%
van de patiënten na zes jaar dienden gereopereerd te worden en slechts 2% van de patiënten
een aortaklep lekkage heeft van graad 2 of meer [12]. Lange termijn resultaten zijn
vooralsnog niet beschikbaar en derhalve kan deze ingreep dan ook nog niet tot de routine
cardiochirurgie gerekend worden. 
Conclusie
Onze initiële ervaring met de reïmplantatie techniek ter behandeling van patiënten met een
aortaworteldilatatie of een Type A dissectie welke tot in de aortawortel doorloopt, is gunstig
verlopen. De korte termijn follow-up toont zeer bevredigende resultaten zowel functioneel
als wat de echocardiografische bevindingen betreft. Het blijft echter noodzakelijk deze
patiënten echocardiografisch te volgen.
Samenvatting
Doel: Het evalueren van een nieuwe chirurgische techniek voor de behandeling van
specifieke aandoeningen van de aortawortel. 
Patiënten : Van 1 januari 1998 tot 31 januari 2000 werden 13 patiënten geopereerd volgens
de aortaklepreimplantatie techniek beschreven door David. De gemiddelde leeftijd was
52.2±11 jaar. De mediane preoperatieve NYHA functionele klasse was 2 en de mediane
preoperatieve aortaklep lekkage 3. De indicatie voor operatie was een aneurysma van de
aortawortel (n=6) of de aorta ascendens (n=4), meestal met secundair ernstige aortaklep
lekkage. In een latere fase van de studieperiode werd de indicatie uitgebreid tot Type A
aorta dissecties met uitbreiding tot de aortawortel (n=3).
Resultaten: Er waren geen technische problemen die een verandering of aanpassing van
de techniek noodzakelijk maakten. De gemiddelde cardiale ischemie tijd en extracorporele
circulatie duur bedroegen respectievelijk 184±40 en 254±74 minuten. Na een gemiddelde
follow-up tijd van 12.3±8 maanden was de mediane aortaklep lekkage 0.5 (p=0.0001 versus
preoperatief) en de mediane NYHA functionele klasse 1 (p=0.02 versus preoperatief).
Histologisch onderzoek van de aortawand toonde de aanwezigheid van primaire media
degeneratie bij vijf patiënten. De overige patiënten vertoonden degeneratieve veranderingen
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in de aortawand. Geen enkele patiënt overleed en er waren geen reoperaties aan de
aortawortel.
Besluit: Op grond van deze eerste ervaringen kan worden gesteld dat de aortaklep re-
implantatie techniek volgens David kan worden uitgevoerd met een zeer laag operatief
risico en een lage graad van residuele aortaklep lekkage. Na de beginperiode werd de
indicatiestelling uitgebreid tot patiënten met een Type A dissectie en ernstige destructie
van de aortawortel.
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Abstract
Objective: The choice of a valve substitute in young adults requires a decision balancing
the risks of long-term anticoagulation versus reoperation(s). This paper analyzes the long-
term risk and determinants of anticoagulation related complications after mechanical aortic
valve replacement. 
Patients and Methods: Between December 1963 and January 1974, 249 patients survived
a mechanical aortic valve replacement at our institution. Mean age was 41.8±12.4 years
and 81% (n=202) were male. Ball valves were implanted in 24% (n=61) and disc valves
in 76% (n=188). Patients were anticoagulated with vitamin K antagonists and antiplatelet
drugs. A total of 4855 patient-years was available for analysis. Mean follow-up was
19.5±9.4 years and was 100% complete. Analyses were performed with Kaplan-Meier and
multivariable Cox regression methods.
Results: One hundred and two patients had one anticoagulation related event and 58 patients
had two events. Six patients had more than five events. Freedom from a first anticoagulation
related event was 74.8±2.9%, 55.3±3.5%, 46.8±4.0% at 10, 20 and 30 years. For a second
event this was 45.4±5.4%, 29±6.0% and 23.2±7.1%. Multivariate predictors for
anticoagulation related complications were ball valve (O.R.=2.9), postoperative endocarditis
(O.R.=2.2) and any surgery (O.R.=2.2). The incidence of events was highest the first five
years postoperatively. 
Conclusions: The risk of adverse events is highest the first five postoperative years. Once
an event has occurred, the risk for a second event is increased. The incidence and frequency
of events is substantial and should be considered in the choice of a valve substitute. 
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Introduction
Aortic valve surgery in young adults requires a complex decision. Traditionally, mechanical
valves are the preferred device since structural failure occurs relatively seldom. However,
mechanical valves require lifelong anticoagulation. Other options include bioprostheses,
allografts, autografts or, for a minority, valve repair. None of these strictly requires
anticoagulation but long-term follow-up is limited and structural failure with subsequent
reoperation occurs more frequently in comparison with mechanical devices [1-4]. 
Since a considerable proportion of patients in need of an aortic valve replacement still
has 25 to 50 years life-expectancy, it is important in the decision-making to consider the
lifelong risk of anticoagulation related complications in case of a mechanical valve
substitute. Some papers in literature deal with long-term follow-up after mechanical valve
replacement [5-8]. However, the follow-up seldomly reaches more than 25 years and is
hardly ever complete. Besides, most studies censor the patient at the first event for a given
complication, hereby neglecting subsequent events. It is therefore extremely difficult to
estimate the real incidence of anticoagulation related complications. 
The present study focuses on the very long-term follow-up after mechanical aortic valve
replacement with specific emphasis on the occurrence and frequency of anticoagulation
related complications and its determinants. 
Methods
Patient selection
December 1963 was the start of the aortic valve replacement program at our institution
and we considered the first 10 years of this program (December 1963 through January 1st
1974). A total of 312 patients underwent aortic valve replacement during this time frame
of whom all hospital survivors were included in the study. Reoperations, urgent or
combined procedures were included. Following these criteria, 249 patients were the subject
of further analysis in this report. 
Demographics
Mean age of these 249 hospital survivors was 41.8±12.4 years (range 14 to 68) and 81%
(n=202) were male. Most of the patients had an isolated aortic valve replacement (n=242).
The remainder (n=7) had simultaneous coronary artery bypass grafting (CABG). In a
minority of patients, the aortic valve replacement was a reoperation after a previous
congenital aortic valve commissurotomy (n=13) and in three patients it was a reoperation
after a correction of aortic coarctation. The cause of the valve disease in the remaining
patients was predominantly rheumatic. Preoperative active endocarditis was present in 28
patients (11%). Isolated aortic stenosis was present in 12.4% (n=31) of patients whereas
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isolated aortic regurgitation and mixed disease were present in 42.2% (n=105) and 45.4%
(n=113) respectively. The procedure was elective in 94% (n=233) of the patients and urgent
in the remainder (n=16). The replaced aortic valve was tricuspid in 202 patients (81%) and
bicuspid in 38 patients (15%). It was unknown in nine patients. 
Several types of mechanical valves were used during the study period. Types and number
of implantations per valve type are given in Table 1. Postoperatively, patients were
anticoagulated with vitamin K antagonists in association with an antiplatelet agent (mostly
dypiridamole). The level of anticoagulation was followed with the trombotest and the target
in those days was between 10 and 6% which corresponds with an INR between 2.8 and
4.2 [9]. Patients were regularly followed by the Dutch thrombosis service, a national
organisation with multiple regional offices and especially created to follow anticoagulated
patients in order to coordinate an adequate anticoagulation level. This organisation is run
by nurses and supervised by doctors who determine the anticoagulant dosis according to
predetermined target levels of INR according to the indication for anticoagulation. 
Table 1: Types, era of implantation and number of a specific valve implanted (n=312). 
Type of mechanical valve N Hospital Survivors
Starr-Edwards 1000
(December 1963 - August 1966) 30 10
Starr-Edwards 1200/1260
(September 1966 - June 1968) 37 23
Starr-Edwards 2300
(July 1968 - October 1969) 20 17
Starr-Edwards 2310/2320
(June 1969 - March 1970) 11 11
Bjork-Shiley A.B.
(December 1969 - June 1973) 119 100
Bjork-Shiley A.B.P.
(June 1971 – January 1974) 95 88
Total 312 249
N: number of patients; 
Follow-up 
Follow-up of the patient cohort (which included patients from all over The Netherlands)
was initially performed by 6-monthly outpatient visit, alternatively at our institution and
by the referring cardiologist. All events were carefully noted. A first follow-up study of
the patient cohort was retrospectively conducted in April and May 1975 by the third author.
All preoperative, operative, postoperative and follow-up data were collected. The follow-up
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was complete and an extensive file with all events on each patient carefully noted, was
completed. This study was however never published. 
Until about 1980, all surviving patients were annually seen at the cardiology department
of our institution. Again, all events were carefully noted. After 1980, the volume of
outpatients became considerable and it was decided to restrict the outpatient visits to
patients of our geographical area or patients demonstrating any valve related problem e.g.
patients having a paravalvular leak, patients having had an aortic valve reoperation, etc.
The remaining patients were followed by their referring cardiologist who regularly updated
our department, at least in the first years. 
A repeat follow-up study of this patient cohort was performed by the first author between
May and December 1999. A new individual patient file was created according to the official
guidelines [10]. All definitions of events were according to these guidelines with the
exception of hemolysis which was defined as any raise in LDH non attributable to other
causes. In addition to valve related events, all other events and reoperations were also
recorded. Follow-up information was obtained from the clinical charts at our institution
as well as from other institutions. In addition, every patients’ successive general practitioner
(most patients had a fixed doctor for a prolonged time period), cardiologist and eventually
neurologist was contacted to obtain information. Also, the neurology departments of all
hospitals where patients had been followed, were contacted to detect additional events.
All patient files were personally seen by the first author and scrutinized for events. These
files included official reporting letters as well as any note on a particular patient. Also, in
case of doubt about an exact date of an anticoagulation related event, the Dutch thrombosis
service was contacted for surviving patients after 1985 in order to extract these data from
their database. This database is virtually complete from the late eighties. In addition, we
recorded the anticoagulation treatment for every patient at the time of an event and, if
known, the INR. 
All surviving patients received and completed a questionnaire regarding their present
status and past events. The latter was specifically meant to match the data collected from
the patients’ file with his own personal history. Also, surviving patients were asked about
the frequency of minor bleeding events which were roughly graded as occurring weekly
or more frequently, monthly, yearly or only seldomly. In addition, they were asked whether
it bothered them to take anticoagulation. If the questionnaire was not adequately completed,
patients were contacted by phone in order to have the data as complete as possible. 
All files of deceased patients were carefully examined to detect events and causes of
death. If the cause of death was unknown, family members were searched and contacted
in order to gather additional information.
A total of 4855 patient-years was available for analysis. Mean follow-up was 19.5±9.4
years and was 100% complete. New York Heart Association (NYHA) functional class in
91 surviving patients at follow-up was I in 39% of patients (n=35), II in 46% (n=42) and
III in 15% (n=14). 
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Data analysis 
Data are expressed as the mean ± the standard deviation. Survival and event-free estimates
were determined by life table analysis [11] and expressed as proportion ± the standard
error. Analysis was performed with the SPSS package version 8.0. 
Risk factors for outcome were evaluated using Cox proportional hazard models. The
first event was used as outcome. Associations are presented as hazard ratio’s (i.e. relative
risk) with corresponding 95% confidence intervals. First analyses were performed using
only the risk factor of interest in the Cox univariate model. Those risk factors whose
association showed a statistical significance of less or equal than 0.10 were included into
a multivariate Cox regression model. A priori we evaluated the following risk factors of
which information was collected at baseline: age, sex, year of operation (before/after 1970),
hypertension (systolic pressure 160 or diastolic pressure 95 or treatment), atrial
fibrillation, history of diabetes mellitus, aortic stenosis (peak gradient 75), aortic
regurgitation (definition AR > grade 1), pre-operative endocarditis, type of valve (Starr
Edwards versus Bjork-Shiley), and type of operation (elective/emergency). Postoperative
factors that were evaluated were paravalvular leak, postoperative endocarditis, new onset
of atrial fibrillation, cardiac events and any surgery (other than aortic valve reoperation).
In addition, we evaluated whether baseline characteristics were predictive of a recurrent
anticoagulation related complication. 
Estimates of the linearized incidence rate with corresponding standard errors were
obtained by dividing the number of first events by the corresponding patient-years of
follow-up. The standard error was calculated as the square root of the incidence divided
by the patient-years of follow-up, assuming a poisson distribution. A two-sided p-value
less then 0.05 was considered statistically significant. 
Results
Late mortality
Overall actuarial survival among hospital survivors was 80.3±2.6%, 57.4±3.1% and
33.6±4.2% at 10, 20 and 30 years postoperatively (Fig. 1). The linearized incidence rate
was 3.2±0.3% per year. Causes of death are shown in Table 2. Multivariate independent
risk factors for death were age ( hazard ratio per year increase 1.0 [95% CI 1.0 - 1.1], male
gender (hazard ratio 1.7 [95% CI 1.1 - 2.7], operation before 1970 (hazard ratio 1.6 [95%
CI 1.1 – 2.4], and postoperative endocarditis (hazard ratio 2.2 [95% CI 1.3 - 3.8]. Diabetes
and emergency operation were significantly related to mortality in the univariate model
but not in the multivariate model.
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Figure 1: Overall late survival among hospital survivors (n=249). 
Table 2: Causes of late death (n=158). 
Cause of death N %
Cardiac 95 60.1
Malignancy 20 12.6
C.O.P.D. 5 3.2
Trauma 4 2.5
Other 27 17
Unknown 7 4.4
Total 158 100
N: number of patients; C.O.P.D.: chronic obstructive pulmonary disease
Freedom from cardiac death was 87.9±2.6%, 72.9±2.9% and 51.8±4.2%, at 10, 20 and
30 years postoperatively (Fig. 2). The linearized incidence rate was 1.9±0.2% per year.
Causes of cardiac death are shown in Table 3. Multivariate independent risk factors for
cardiac death were age ( hazard ratio per year increase 1.0 [95% CI 1.0 - 1.1], and operation
before 1970 (hazard ratio 1.9 [95% CI 1.2 - 3.1]. Male sex, type of valve and postoperative
endocarditis were significantly related to cardiac mortality in the univariate model, but not
in the multivariate model.
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Figure 2: Freedom from cardiac death. 
Freedom from valve related mortality was 92±1.7%, 83.3±2.5% and 75.4±3.7% at 10, 20
and 30 years postoperatively. The linearized incidence rate was 0.9±0.1% per year. Causes
of valve related mortality are also shown in Table 3. Multivariate independent risk factors
for valve related mortality were age ( hazard ratio per year increase 1.0 [95% CI 1.0 - 1.1],
and postoperative endocarditis (hazard ratio 2,1 [95% CI 1.1 - 4.2]. Preoperative
endocarditis, emergency operation, and aortic stenosis were significantly related to valve
related mortality in the univariate model, but not in the multivariate model. 
Freedom from anticoagulation related mortality was 97.7±1.3%, 93.2±1.8% and
90.5±3.2% at 10, 20 and 30 years (Fig. 3). The linearized incidence rate was 0.3±0.1%
per year. Out of a total of 14 events, 8 were due to bleeding events whereas the remainder
were due to thrombo-embolic phenomena (including 4 patients with valve thrombosis –
see Table 3). Only age was an independent predictor for anticoagulation related mortality
with a hazard ratio per year increase of 1.1 [95% CI 1.0 -1.2]. Diabetes and emergency
operation did not reach statistical significance in the multivariate model. 
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Table 3: Causes of cardiac death (n=95). 
Cause N %
Heart failure 43 45.3
Myocardial infarction 7 7.4
Arrhythmia 0 0
Valve related:    -     sudden death 26 27.4
- valve thrombosis 4 4.2
- thrombo-embolic event 2 2.1
- bleeding event 8 8.4
- endocarditis 5 5.3
Total 95 100
N : number of patients
Figure 3: Freedom from anticoagulant related death. 
Anticoagulation related complications (any type)
One hundred and two patients experienced an anticoagulation related complication, in the
absence of endocarditis, during follow-up. The majority of patients experienced one or
two events (n=102 and 58 respectively) but nevertheless, 30 patients experienced three
events and 13 patients four events. Six patients had more than five events and one patient
even more than 10 events. 
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Figure 4: Freedom from a first anticoagulant related complication. 
Figure 5: Freedom from a first, second and third anticoagulant related event. Note the increased slope
of the multiple-events curves which indicates an increased risk of subsequent events once a first event was
encountered.
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Freedom from a first anticoagulation related event was 74.8±2.4%, 56.3±3.5% and
46.8±4.1% at 10, 20 and 30 years postoperatively (Fig. 4). Multivariate predictors for a
first anticoagulation related complication were ball valve (hazard ratio 2.9 [95% CI 1.2 -
7.2], postoperative endocarditis (hazard ratio 2.2 [95% CI 1.2 - 4.0], any surgery other than
aortic valve reoperation (hazard ratio 2.2 [95% CI 1.3 - 3.7]. Atrial fibrillation and
operation before 1970 did not reach statistical significance in the multivariate model. The
linearized incidence rate of a first event was 3.0±0.3% per patient-year. 
Freedom from a second anticoagulation related event after the first event was 45.4±5.4%,
29±6.0% and 23.2±7.1% at 10, 20 and 30 years postoperatively (Fig. 5). None of the risk
factors reached a statistical significant level in association with recurrent events. 
The risk of anticoagulation related complications was highest within the first five years
after aortic valve replacement, after which the risk decreased (Table 4).
Table 4: Incidence of valve related morbidity during follow-up. Values are 5-years cumulative incidence
(with corresponding standard errors) of the event. 
Event Follow-up period (years postoperatively)
0 – 4.9 5 – 9.9 10 – 14.9 15 – 19.9 20 – 24.9 25 – 29.9
ARC 4.5±0.6 1.8±0.5 3.0±0.7 2.9±0.7 1.8±0.7 2.3±1.1
Thromb. 0.3±0.1 0 0.3±0.2 0 0 0
TE 2.7±0.5 1.7±0.4 1.5±0.4 1.7±0.5 1.5±0.6 2.0±1.0
Bleed. 1.3±0.3 0.5±0.2 1.1±0.4 1.9±0.5 0.7±0.4 0.4±0.4
Endoc. 0.5±0.2 0.5±0.2 0.2±0.2 0.4±0.2 0.2±0.2 0.7±0.5
Reop. 1.6±0.4 0.8±0.3 0.8±0.3 0.6±0.3 0.9±0.4 1.5±0.8
ARC: anticoagulation related complication; Thromb.: valve thrombosis; TE: thrombo-embolic event; Bleed.:
bleeding event; Endoc.: endocarditis; Reop.: aortic valve reoperation
& Valve thrombosis
Valve thrombosis, in the absence of endocarditis, occurred six times. None of these patients
was adequately anticoagulated at the time of the event. In two instances, the patients did
not even take vitamin K antagonists which they had stopped spontaneously. The linearized
incidence rate of valve thrombosis was 0.1±0.1% per patient-year. Table 4 shows the
occurrence of valve thrombosis during follow-up. Freedom from valve thrombosis was
98.7±0.7%, 97.0±1.0% and 97.0± 1.1% at 10, 20 and 30 years postoperatively. 
& Thrombo-embolic phenomena
 A total of 140 thrombo-embolic (TE) phenomena (excluding valve thrombosis) took place
in 77 patients who did not have endocarditis at the time of the event. A second event was
experienced by 28 patients, a third event by 17 patients and a fourth event by four patients.
Transient ischaemic attack (TIA) occurred in the majority of cases: 82 events in 47 patients.
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Stroke occurred 35 times in 28 patients. A minority of the TE events were peripheral emboli
(seven events in six patients). Sixteen events were classified as ‘other’ including nine
probable embolic events (according to history) and seven non-specified. Lethal outcome
was noted in 2.6% (2 events) of the TE events. The INR at the time of the first event was
known in 23 patients (30% of the events). Mean INR at the time of the event was 1.9±1.2
and 85% of these values were below the target baseline of 2.8. Sixty seven% of the values
were even below 2.0. Of all 140 TE events, 12.8% of the patients (n=18) were not using
anticoagulant drugs at the time of the event.
Freedom from the first TE event was 79.9±2.6%, 68.5±3.3% and 57.3±4.3% at 10, 20
and 30 years postoperatively (Fig. 6). Multivariate independent risk factors for first
thrombo-embolic event, excluding valve thrombosis, were age (hazard ratio per year
increase 1.0 [95% CI 1.0 - 1.0], operation year before 1970 (hazard ratio of 2.2 [95% CI
1.3 - 3.7]), and not using anticoagulant drugs at the time of the event (hazards ratio 4.1
[95% CI 2.1 - 8.0]. Atrial fibrillation was significantly related to first thrombo-embolic
event in the univariate model, but not in the multivariate model.
 The linearized incidence rate of a first TE event was 2.0±0.2% per patient-year. Freedom
from a second TE event after the first event was 73±5.3%, 63.6±6% and 49.9±7.8% at 5,
10, and 15 years postoperatively (Fig. 7). In the analysis of the determinants of a recurrent
TE event, none of the risk factors reached a statistically significant level. 
The incidence of TE events was higher within the first 5 postoperative years, after which
it remained relatively constant (Table 4).
Figure 6: Freedom from a first thrombo-embolic (T.E.) event.
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Figure 7: Freedom from a first, second and third thrombo-embolic (T.E.) event. Note the increased slope
of the multiple-events curves which indicates an increased risk of subsequent events once a first event was
encountered.
& Major bleeding events
A total of 72 major bleeding events, in the absence of endocarditis, occurred. There were
47 first events whereas 15 patients had a second event and 6 a third event. A minority of
the events were cerebral bleeding with residual impairment (n=14); lethal outcome was
noted in eight patients. The remainder were non-cerebral bleeding events requiring
transfusion or surgical evacuation (50 events). All the patients with bleeding events were
taking oral anticoagulation at the time of the event. The INR at the time of the first event
(n=47) was known in 13 cases. Mean INR was 4.7±1.8 and 69% of these values were above
the target maximum INR of 4.2. Freedom from a first bleeding event was 91.1±1.9%,
78.6±2.4% and 74.1±3.4% at 10, 20 and 30 years postoperatively (Fig. 8). Multivariate
independent risk factors for a first bleeding event were increasing age (hazard ratio per
year increase 1.0 [95% CI 1.0 - 1.1]) and any surgery (hazard ratio 3.8 [95% CI 2.0 - 7.7]).
Atrial fibrillation was significantly related to first bleeding event in the univariate model,
but not in the multivariate model. 
The linearized incidence rate of a first bleeding event was 1.1±0.2% per patient-year.
Freedom from a second bleeding event after the first event was 78.7±4.2%, 69±7.6% and
58.3±9.5% at 5, 10, and 15 years postoperatively (Fig. 9). In the analysis of the
determinants of a recurrent bleeding event, none of the risk factors reached a statistically
significant level. 
The incidence of bleeding events was relatively constant over time (Table 4). 
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Figure 8: Freedom from a first bleeding event. 
Figure 9: Freedom from a first, second and third bleeding event. Note the increased slope of the curves
with multiple events, indicating an increased risk of subsequent events once a first event was encountered.
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& Minor bleeding events
The frequency of minor bleeding events was estimated by the 91 survivors and graded as
very seldom (n=59), yearly (n=17), monthly (n=5) and weekly or more (n=10). 
& Attitude towards anticoagulation
Among 91 survivors, 13 patients would prefer not to take anticoagulation whereas 75
patients did not care. The remainder had no opinion. 
Other valve related events
& Valve dysfunction
There were no structural valve deteriorations. Leaflet obstruction due to pannus overgrowth
necessitating reoperation occurred in two patients.
& Paravalvular leak
Paravalvular leak occurred once in 28 patients, twice in 3 patients and 3 times in 1 patient.
The linearized incidence rate was 0.7±0.1% per patient-year. Paravalvular leak was the
major cause of aortic valve reoperation (Table 5). 
& Hemolysis
Hemolysis occurred frequently with a linearized incidence rate of 4.2±0.4% per patient-year
(n=118). The majority of the hemolysis events occurred within the first 5 postoperative
years (n=93). However, hemolysis was only once the leading cause of reoperation
(Table 5).
& Endocarditis
Postoperative endocarditis occurred in 20 patients. The linearized incidence rate of
endocarditis was 0.4±0.1% per patient-year. The incidence of postoperative endocarditis
was relatively constant over time (Table 4). 
& Aortic valve reoperation
A total of 60 aortic valve reoperations occurred in 46 patients. Twelve patients underwent
a third aortic valve operation and 2 patients a fourth. Causes of aortic valve reoperation
are listed in Table 5. Paravalvular leak was the leading cause occurring in 60.6% of cases
(n=37). Freedom of aortic valve reoperation was 88.7±2.1%, 82.4±2.7% and 67.5±6.2%
at 10, 20 and 30 years postoperatively. The linearized incidence rate was 1±0.1% per
patient-year. The incidence of aortic valve reoperation was highest within the first 5
postoperative years and beyond 25 years of follow-up (Table 4). None of the patients died
at aortic valve reoperation. 
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Table 5: Causes of aortic valve reoperation (60 events in 46 patients). 
Cause 1  reop. (N) 2  or 3  reop. (N)st nd rd
Valvular dysfunction 2 0
Paravalvular leak 29 8
Endocarditis 1 1
Valve thrombosis or recurrent thrombo-emboli 5 1
Hemolysis 1 0
Other 8 4
Total 46 14
N : number of events; reop.: reoperation
Other events
& Other reoperations
A total of 25 cardiac reoperations, other than aortic valve reoperations occurred in 20
patients. They included CABG (n=9), mitral valve operation (n=9), ascending aortic
replacement (n=2) and other (n=5). A total of 27 pacemakers were implanted during follow-
up. 
A total of 199 other, non-cardiac, surgical interventions took place in 100 patients.
Freedom from any first surgical intervention (excluding aortic valve reoperation) was
71.2±3.1%, 48.3±3.7% and 28.8±4.5% at 10, 20 and 30 years postoperatively. 
& Other cardiac events (exclusive cardiac mortality)
A total of 395 cardiac events in 168 patients were noted during follow-up. They included
heart failure (87 events), myocardial infarction (24 events), angina (35 events),
supraventricular arrhythmias (93 events), ventricular arrhythmias (41 events), electrical
cardioversions (31 events), hypertension treatment (n=43) and other (41 events). Freedom
from any first non-operative cardiac event was 56.7±3.3%, 33.1±3.3% and 12.8±4.8% at
10, 20 and 30 years postoperatively.
Comment
Adults requiring an aortic valve replacement at a young age still have a long life
expectancy. Traditionally, mechanical valves are the substitute of choice because of
excellent performance and rare structural failure, therefore limiting the risk of reoperation
[7]. However, mechanical valves require life-long anticoagulation with an inherent
complication rate. It is therefore important to balance the life-long risk of anticoagulation
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related complications against the risk of (multiple) reoperation(s) when a tissue valve or
a valve repair would have been performed. 
The present study examined the very long-term incidence of anticoagulation related
complications after mechanical aortic valve replacement. We analyzed the first 10 years
of our institutional experience which reached a mean follow-up of almost 20 years. Even
more important, to accurately investigate the incidence of complications, the follow-up
was 100% complete. 
Global anticoagulation related complications 
In agreement with previous publications, the incidence of anticoagulation related
complications was fairly high [8, 12-16]. In the present series, only 46.8% of the patients
remained free from a first anticoagulation related event at 30 years postoperatively.
However, the linearized incidence rate for a first event in the current series was 3% per
patient-year which compares favorably with reported incidence rates of 3-5% for the Starr-
Edwards valve [8, 13] and an overall incidence of approximately 3.5% for the Bjork-Shiley
standard valve [13]. 
In addition to a first event, 58 patients (23.3%) had 2 events, 30 patients (12%) a third
and 13 patients (5.2%) a fourth event. While this incidence is certainly substantial, the
present series demonstrates that only few patients experienced more than 4 events over
the entire study period. However, Fig. 5 demonstrates that patients who had a first event
are at increased risk for subsequent events. 
Although literature usually reports TE phenomena and bleeding complications
separately, we also wanted to report the global complication rate since, for a given patient,
one wants to inform about the global risk of any anticoagulation related complication.
Besides, patients experiencing a TE or bleeding event are by no means separate patient
groups but overlap considerably, as previously reported [17]. 
Interestingly, one of the risk factors for anticoagulation related complications was the
occurrence of any surgery other than aortic valve reoperation, during follow-up (O.R.=2.2).
Anticoagulation is commonly interrupted and the patient is protected from adverse events
with intravenous heparin [15, 18]. The risk of this interruption has been estimated [16] and
reported [18] to be low but nevertheless emerges as a risk factor in the present series. It
is conceivable that fluctuations in levels of anticoagulation make the patient more prone
to complications as both the intensity and consistency of the anticoagulation are important
factors in avoiding adverse events [13, 15]. 
Thromboembolic events
A total of 77 patients (31%) had TE events. Of these, 28 (11.2%) experienced multiple
events. Out of a total of 140 TE events, two had lethal outcome and 35 were strokes with
residual impairment. This high incidence of 26.4% is undoubtedly related to the fact that
85% of the known INR at the time of the TE event were below the target baseline.
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Inadequate or stopped anticoagulation is known to be strongly associated with increased
risk of TE events [15-17] as also evidenced by the hazard ratio of 4.1. On the other hand,
the current first event linearized incidence rate of 2% per patient-year is very comparable
with previously reported rates of 2 – 2.8% per patient-year for the Bjork-Shiley and Starr-
Edwards valve [7-8, 19]. Equally, the 10 year freedom from a first TE event is situated
around 80% which is however lower than the 86.7% reported by the Mayo Clinic in their
long-term follow-up study of Starr-Edwards valves [20]. 
As for the global anticoagulation related complications, patients who had a first TE event
were at increased risk for multiple events (Fig. 7). 
Bleeding events
Major bleeding events occurred in 47 patients (72 events). Outcome for bleeding events
was generally worse than for TE events (8 lethal events versus 2) as already stated by
Cannegieter et al. [21]. Although the INR was known in only a minority of bleeding events,
most of these INR’s were above the target maximum, in accordance with literature [14-18,
21-22]. 
The linearized incidence rate of 1.1% for first bleeding event in this series is better than
in the previously mentioned studies [7-8, 13] where rates of 1.2 to 2.2% per patient-year
were found. An exceptionally high incidence rate of 5% per patient-year was found in the
study by Borkon et al. without obvious reason [19]. In the conference discussion of that
paper it was suggested that the favourable incidence of anticoagulation related
complications in the Netherlands was probably thanks to the nationally organized
thrombosis service. However, equally good or even better results have also been reported
without the aid of such an organisation [20]. 
As for the global anticoagulation related complications and the thromboembolic events,
patients with a first event were at increased risk for subsequent events (Fig. 9). 
Practical inferences
One hundred and two patients (41% of all study patients) had 37 major TE events (out of
140 events), six valve thromboses and 72 major bleeding events. This means that of a total
of 218 anticoagulation related events, with the exception of minor bleeding events, 115
or 53% were major events. In addition 6.4% of all events were lethal. This high proportion
has occurred despite the fact that the target INR of 2.8 to 4.2 was not much different from
the current recommendations: according to literature, the overall target INR should be
between 2.5 and 4.0 [21-24]. It is therefore clear that, although INR levels were regularly
followed by a specialized organization who closely followed the official guidelines for
anticoagulation, the incidence of anticoagulation related events on the very long-term is
still considerable and above all in this series not substantially worse than other published
series. It was the purpose of this study to determine this long-term incidence which in itself
should be born in mind whenever a doctor is advising a young adult who needs aortic valve
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surgery. The counterpart of the balance will be determined by the risk of (multiple)
reoperation(s) for failing bioprostheses or valve repair. 
Age per year was in the current series a risk factor for both TE events and bleeding
events. This is still controversial in literature as it confirms the findings by Cannegieter
et al. [19] but contradicts the findings of several other studies [5, 13-14, 17, 25-26]. The
fact that younger age could be less prone to complications than older age may be an
argument in favor of mechanical aortic valve replacement.
Of all other identified risk factors, only the type of valve and careful consistent
anticoagulation regimen are correctable factors. As the incidence of anticoagulation related
complications was highest during the first 5 years, but remained present throughout the
study period, careful monitoring seems the most important determinant of outcome. 
Limitations of the study
The present series is a retrospective analysis over a long time period. This inevitably raises
the concern of the completeness of our data collection despite major efforts to reduce this
error to a minimum. While it is unlikely that we missed major events, the registration of
minor events (especially minor bleeding events) was more difficult. The reported risk may
thus be underestimated and the proportion of major events consequently overestimated.
A limitation is the lack of registration of preoperative neurological events. Some reports
indicate history of neurological events as a risk factor for future events [15, 21], but the
original 1975-follow-up of the patient cohort did not register this information and we were
therefore unable to evaluate this variable. However, the demographics of the patient
population suggest that probably only very few patients might have had a preoperative
neurological event: mean age was 41.8 years, only 13 patients (5.2%) had an aortic valve
reoperation and only seven patients (2.8%) had simultaneous CABG (indicative of systemic
atherosclerosis). It is therefore unlikely that the lack of this information affected our risk
estimates.
Another remark concerns the valves implanted in the series. Ball valves were implanted
in 24% of hospital survivors and tilting disc valves in the remainder. While these valves
are known to have an increased risk of anticoagulation related complications as compared
to the more recently available bileaflet mechanical valves [7-8, 13, 15-16, 18, 21-22, 27],
ball valves and tilting disc valves are currently still being implanted. Moreover, some recent
reports suggest a lower target INR in current bileaflet valves with consequently lower
bleeding complications without increasing TE events [28-29]. It is undoubtful but yet
unproven that the very long-term incidence of anticoagulation related complications with
the currently available bileaflet prostheses will be less than the currently reported incidence.
With this in mind, we feel that the present series should serve as a reference for future very
long-term follow-up studies. 
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Conclusion
At 30 years follow-up, 46.8% of the patients remained free of any anticoagulation related
complication and about one fourth of the patients (23.3%) experienced multiple events.
This incidence of adverse events should be considered whenever aortic valve surgery is
considered for a particular patient.
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Introduction
The aim of the present thesis was to define the feasibility and durability of aortic valve
reconstructive surgery in adults. As in mitral valve repair, reconstructive surgery of the
valve is highly dependent on the anatomy of the valve as well as the anatomy and
interaction of the structures influencing valve competence. The normal aortic valve consists
of three valvular cusps attached in a semilunar fashion along the annulus fibrosus.
Congenital variations that may result in a failing aortic valve in adulthood have a different
number of cusps : one cusp in the unicuspid aortic valve (this is rare), two cusps in the
bicuspid aortic valve (this is by far the most common congenital variation), and four cusps
in the quadricuspid aortic valve (this is also rare) [1]. The aortic valve cusps (irrespective
of their number), the aortic valve annulus, the sinuses of Valsalva and the sinotubular
junction constitute the aortic root and their interaction determines proper aortic valve
functioning [2].
In adults, there are essentially two pathological conditions of the aortic valve : aortic
stenosis and aortic regurgitation [3]. These two conditions may also co-exist which is then
called ‘mixed’ aortic valve disease. Aortic stenosis in adults is situated at the level of the
aortic valve cusps and is due to an insufficient opening of the these cusps. Mixed aortic
valve disease is due to insufficient opening and closing of the aortic valve, resulting in
aortic stenosis and aortic regurgitation. Both pathological conditions are generally managed
by aortic valve replacement when intervention is indicated. Indeed, attempts of valve repair
for aortic stenosis have been associated with high failure rates [4-6] and are largely
abandoned. 
In contrast to aortic stenosis, aortic regurgitation in adults may be caused at different
levels of the aortic root. At the level of the aortic valve leaflets, aortic regurgitation may
be caused by leaflet retraction due to rheumatic aortic valve disease, by leaflet prolapse
or by leaflet perforation. Aortic regurgitation may also be due to dilatation of the
sinotubular junction in the presence of normal aortic valve leaflets [7]. This dilatation can
occur in aneurysms of the sinuses of Valsalva and/or ascending aorta. In addition,
destruction of the aortic root in acute Type A aortic dissection will lead to dilatation of
the sinotubular junction and commissural prolapse with subsequent aortic regurgitation.
Aortic valve repair for rheumatic aortic regurgitation has been reported previously [8-10].
The short-term results were satisfactory but long-term results have shown a disappointing
failure rate [11]. It seems therefore unreasonable to advocate valve repair for rheumatic
aortic regurgitation, except in countries where budgets for expensive valve substitutes are
limited, or where adequate control of oral anticoagulation is difficult. 
Aortic valve repair for leaflet perforation, usually due to endocarditis, is a feasible
option. Patch closure of the perforation restores aortic valve competence [12]. In order to
be successful, the defect has to be fairly small and may not interrupt the continuity of the
leaflet circumference. This is relatively rare and was therefore not further described in this
thesis. 
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The present thesis considers the remaining indications for conservative aortic valve surgery:
aortic regurgitation due to leaflet prolapse (chapters 2 and 3), and aortic regurgitation
resulting from a distorsion and/or dilatation of the sinotubular junction (chapters 4 and 5).
In order to validate aortic valve repair in these conditions, one has to balance the results
of aortic valve repair against the possible disadvantages of valve replacement. 
For bioprosthetic aortic valve replacement, this includes the risk of structural
deterioration with subsequent need of reoperation. This is a complex issue since reoperation
of an aortic valve bioprosthesis can be indicated for intrinsic structural failure (which in
turn can depend on possible comorbidity, e.g. dialysis), for structural failure due to
endocarditis (and the risk of endocarditis may be different for different types of valve
substitutes), associated replacement of an aortic valve bioprosthesis during surgery for
primarily other indications like mitral valve pathology, or coronary artery disease, …. The
complexity of this issue precluded further analysis of this topic in the current thesis. 
For mechanical aortic valve replacement, the main disadvantage is the lifelong necessity
and risk of oral anticoagulation. Since many studies censor the patients at the first
anticoagulation related event, it is hardly possible to estimate the real incidence of
anticoagulation related events since the same patient may experience multiple events.
Therefore, a long-term follow-up study after mechanical aortic valve replacement was
performed to estimate the incidence, frequency and severity of anticoagulation related
events. 
This thesis therefore focuses on the following questions : what are possible indications
for repairing the regurgitant aortic valve; are these operations technically feasible and what
is their durability; and finally, what is the long-term incidence, frequency and severity of
anticoagulation related events after mechanical aortic valve replacement? 
Aortic regurgitation due to cusp prolapse (chapters 2 and 3)
 
Aortic regurgitation may result from leaflet prolapse which prohibits correct apposition
of the valve leaflets in diastole [12]. Leaflet prolapse may occur in the bicuspid and
tricuspid aortic valve as is described in Chapters 2 and 3. Efforts to eliminate aortic
regurgitation should aim at restoring normal leaflet configuration. This is accomplished
by a triangular resection of the prolapsing area, or its plication. Both of these techniques
can be used in either the bicuspid or the tricuspid aortic valve. To date, no differences in
outcome (durability) between the two techniques have been documented. However, a
plication is easier to accomplish since it eliminates the difficult decision of the correct
amount of tissue that should be resected. Moreover, the plication of tissue provides a
stronger basis to hold the suture and preserves more coaptation area (chapter 2). 
As pointed out in Chapter 3, the technique of repair is more difficult in tricuspid aortic
valves compared to bicuspid aortic valves. This is undoubtedly due to an easier reference
in bicuspid aortic valves where the two leaflets are exactly opposed to each other. Besides,
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valve tissue in bicuspid aortic valves is usually thicker than in tricuspid aortic valves. This
explains the considerable immediate repair failure (15%) in the tricuspid group (chapter 3).
One could argue about a repair attempted in a bicuspid aortic valve, since this is a
congenitally abnormal valve. However, it is known that about 64% of patients with a
bicuspid aortic valve will never develop functional aortic valve pathology [13]. It is
therefore an attractive idea to try to ‘relocate’ a patient with a regurgitant bicuspid aortic
valve into the group of patients whose bicuspid valve will perform satisfactorily throughout
the rest of their life.
Another remark concerns the evidence of aortic wall abnormalities in patients with a
bicuspid aortic valve [14]. Repairing the aortic valve in these patients leaves the aortic
tissue intact and subsequent aortic dilatation may cause central aortic regurgitation [7, 15].
This is certainly an important issue. Echocardiographic studies in our patient group could
not demonstrate such an aortic dilatation but our mean follow-up was only 5 years. It is
thus important to follow these patients at regular intervals. This is true for all patients with
a known bicuspid aortic valve since they are at increased risk for aortic dissection when
compared with normal subjects [16-19]. 
The freedom from aortic valve reoperation was 84% at 7 years in the bicuspid aortic
valve group and 83% at 5 years in the successfully repaired tricuspid aortic valve group.
These results indicate a rather high failure rate. However, these patients do not need
anticoagulation which is of particular importance in patients with an active life-style or
women of child-bearing age. The use of anticoagulation has a significant incidence of
adverse events (see chapter 6), and is known to cause congenital abnormalities in pregnant
women [20]. Moreover, subcutaneous heparin in pregnant women does not prevent
thromboembolic phenomena [21]. For these reasons, patients might want to take the risk
of reoperation which in the presented series had no mortality. In addition, it seems
reasonable to assume that the risk of reoperation after valve repair will probably prove to
be lower than after aortic valve replacement. 
In conclusion, aortic valve repair for prolapsing leaflet seems a very reasonable treatment
option, particularly in patients who want to avoid anticoagulation. 
Aortic regurgitation due to distorsion or dilatation of the sinotubular junction
(chapters 4 and 5)
Even though the aortic valve may be structurally entirely normal, aortic regurgitation can
result from distorsion or dilatation of the sinotubular junction [7]. This causes failure of
cusp coaptation during diastole with subsequent, usually central, regurgitation. Conditions
possibly associated with distorsion or dilatation of the sinotubular junction are Type A
aortic dissection (chapter 4), aneurysms of the aortic root and ascending aortic aneurysm.
The latter two conditions may exist separately, or co-exist (chapter 5). Restoring the aortic
root geometry and sinotubular junction will restore aortic valve competence. 
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Valve preservation in acute Type A aortic dissection
Chapter 4 studies the outcome of aortic valve preservation in the surgical treatment of Type
A aortic dissection with involvement of the aortic root. At a mean follow-up of 44 months,
12.6% of the hospital survivors had an aortic valve/root reoperation, all with aortic valve
replacement. Interestingly, only one reoperation was due to an intrinsic abnormality of the
aortic valve, a dehiscence of the commissuroplasty (see Table 6). All other reoperations
were due to other causes: graft infection (n=1), false aneurysm (n=1) and aortic root
dilatation (n=9). In retrospect, with the exception of the patient with graft infection and
the failed commissuroplasty, it should have been possible to save the aortic valve at
reoperation. A false aneurysm should not imply an aortic valve replacement, and all patients
with aortic root dilatation could have benefited from the valve sparing operation described
in chapter 5. Besides, as stated in the conclusions of chapter 4, given the relatively high
incidence of native aortic root dilatation at follow-up, we currently favour this ‘David’
procedure (see chapter 5) in Type A dissection with involvement of more than one sinus
of Valsalva. 
A possible contributing factor for aortic regurgitation associated with aortic root
dilatation is prosthetic dilatation. All prostheses were anastomosed to the native aorta at
the level of the sinotubular junction and prosthetic dilatation may therefore cause aortic
regurgitation. Prosthetic dilatation has been described, both in the abdominal and thoracic
aorta, and is more pronounced in knitted than woven prostheses [22-23]. Knitted prostheses
were used in the majority of the patients. Our follow-up echocardiograms did not
sufficiently register aortic measurements at the level of the ascending aorta. Hence, it is
impossible to estimate the impact of prosthetic dilatation on the occurrence of late aortic
regurgitation. However, the majority of the patients were reoperated for aortic root
dilatation which, in this particular study, was due to native aortic tissue dilatation. Despite
the lack of evidence for prosthetic dilatation as a cause of subsequent aortic regurgitation
in the present study, it might be wise to reinforce the prosthesis at the level of the
sinotubular junction with an external wrap of Teflon® felt or pericardium. Whenever
prosthetic dilatation occurs, dilatation of the sinotubular junction could be prevented in
this way. 
Aortic valve reimplantation technique (‘David procedure’)
Chapter 5 describes the initial experience with the David procedure. This technique
completely replaces the aortic root with the exception of the aortic valve which is
reimplanted in a tubular Dacron prosthesis [24-27]. Our initial experience is encouraging:
aortic regurgitation is eliminated, and the functional capacity of the patients is substantially
improved.
Although the results reported by David and our initial experience are encouraging, some
concern exists about this ‘new’ aortic root. Indeed, this reconstruction abolishes the sinuses
of Valsalva which are known to share diastolic stress with the aortic valve leaflets, thereby
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probably playing a role in leaflet longevity [28]. If the sinuses are absent, all diastolic stress
will now be exerted on the valve leaflets. It is specifically for this reason that another
technique was developed by Yacoub (historically, this technique was actually developed
first but promoted less and hence is less known by the cardiac surgical community) [29-30].
This technique replaces the diseased sinuses by three separate, tongue-shaped extensions
of the Dacron tube. Comparison of both techniques by echocardiographic studies
demonstrated some sinus of Valsalva-like function in Yacoub’s technique and also near-
normal opening and closing characteristics of the aortic valve [31]. This was not the case
with David’s technique which, in addition, showed systolic contact between the aortic valve
cusps and the Dacron tube. This may cause leaflet abrasion and therefore compromise
leaflet longevity. 
Recent additional evidence of the importance of the sinuses of Valsalva has been
provided by Grande-Allen et al. [32]. This group studied the impact of three valve-sparing
techniques on leaflet stress: David’s technique, Yacoub’s technique and a recent
modification of David’s technique creating a pseudo-sinus [33]. All three techniques
significantly altered leaflet stress patterns but the pseudosinus model showed the smallest
increase in stress and leaflet coaptation was closest to normal. 
Since long-term follow-up with any of these techniques is limited, further observation
of the patients seems mandatory to detect clinical consequences of theoretical observations.
In conclusion, the results of aortic valve preservation for acute Type A dissection can still
improve as about 12% of hospital survivors are reoperated within four years. The main
reason for reoperation was native aortic root dilatation. This problem may be solved by
applying any aortic valve sparing technique at the time of the initial operation. Long-term
follow-up with these techniques is however still lacking. 
Long-term anticoagulation 
All aortic valve reconstructive, or leaflet reimplantation techniques avoid the necessity of
oral anticoagulation. The durability of these techniques is however still inferior to
mechanical valve prostheses. In all of the above procedures, the incidence of reoperation
is higher than that after mechanical aortic valve replacement [34]. On the other hand, when
choosing for a mechanical valve substitute, one needs to consider the risks associated with
oral anticoagulation. Chapter 6 demonstrates that this risk is substantial at a mean follow-up
of 20 years (up to 33 years), at least with the studied types of valve prostheses in this
particular Dutch patient population. Almost half of the patients experienced at least one
event, 23% had multiple events, and about half of all events were major with a variable
degree of permanent residual deficit. This high incidence of events occurred despite the
existence of the ‘Dutch Trombosedienst’, a national organisation especially created to
follow and manage anticoagulated patients according to preset standards. It is conceivable
that, due the lack of such an organisation, the incidence of anticoagulation related events
Discussion
113
in other countries is even higher. This incidence can probably be somewhat reduced by
rigorous anticoagulation management since most of the patients with known INR at the
time of the event were not appropriately anticoagulated. It is however impossible to prevent
any patient from withdrawing, or inadequately taking anticoagulant drugs, and
anticoagulation will therefore always keep its related complications. 
One may argue that the prostheses studied are older types. This is correct but some are
still in use. Also, long-term follow-up studies of this kind obligatorily have to deal with
older prostheses. Some reports suggest lower anticoagulation levels with the modern
bileaflet prostheses without increasing adverse events [35-36]. Hopefully, the long-term
incidence of adverse events with these newer types of prostheses will prove to be lower
than the unacceptable high rate in the present study. 
Conclusion
Whenever a patient needs aortic valve surgery, one should consider valve repair. The
current indications for aortic valve repair in modern western society are localized leaflet
perforation, cusp prolapse and regurgitation secondary to sinotubular distorsion or
dilatation. The preoperative echocardiogram is able to provide sufficient information to
estimate the technical possibilities for valve repair. The surgeon and the patient will have
to balance the risk of repair failure against the risk of adverse events associated with valve
replacement. The present thesis demonstrates that conservative aortic valve surgery is
feasible with reasonable mid-term outcome. Chapters 2, 3 and 4 have a 5-year freedom
from reoperation of 87%, 84% and 89% respectively. Experience with aortic valve sparing
operations in the present thesis was still limited but a 5-year freedom from reoperation of
97 and 89% has been documented [27, 30]. All other surgical options include valve
replacement, either with mechanical devices, bioprostheses, autografts or allografts. As
discussed in chapters 1 and 6, all of these also have disadvantages. In particular, mechanical
aortic valve replacement with its need for life-long oral anticoagulation is associated with
a substantial risk of adverse events over a long time period: almost half of the patients had
adverse events; 23% had multiple adverse events and half of the events resulted in
permanent deficit. 
It is time to further improve repair techniques and to develop more durable prostheses
avoiding oral anticoagulation! 
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Summary
Chapter 1 reviews the current knowledge of the aortic valve. The normal anatomy and
possible variations are described. The different pathological conditions are explained as
wel as their natural history and the indications for intervention. The various surgical options
with regard to the pathological condition are described. In particular, the results of aortic
valve repair, when available, are presented. All other types of aortic valve substitutes are
also described and their main advantages and disadvantages are mentioned. Finally, the
aim of the present thesis is defined. 
Chapter 2 studies the durability of bicuspid aortic valve repair for prolapsing leaflet.
Ninety-four patients were operated over an 8-year period with a mean follow-up of 5 years.
Successful repair was more difficult to achieve in dilated ventricles. A total of 12 patients
underwent reoperation. In three of them, the aortic valve was re-repairable. The risk of
reoperation was highest the first postoperative year and then relatively constant at 2% per
year. The overall freedom from aortic valve reoperation was 84% at 7 years. The repair
was less durable in patients with residual aortic regurgitation after the initial procedure.
Chapter 3 examines the results of valve repair in tricuspid aortic valves with leaflet
prolapse. The repair was attempted in 33 patients but failed immediately in five. During
a mean follow-up of 4 years, three more patients required aortic valve replacement. The
freedom from aortic valve reoperation after successful initial repair was 83% at 5 years.
The size of the patient group and the number of events were too small to detect risk factors
for repair failure. 
Chapter 4 is an analysis of the results of aortic valve preservation during surgical
intervention for acute Type A aortic dissection with involvement of the aortic root. From
1976 to 1999, 121 patients were operated with various techniques for aortic root
reconstruction and followed for a mean of almost 4 years. Ten percent of the patient
population underwent aortic valve replacement during follow-up but only one was due to
intrinsic aortic valve pathology. Nine reoperations were due to aortic root dilatation. The
use of fibrinous glue for aortic root reconstruction and the presence of an aortic valve
annulus > 27mm were associated with a statistically significant higher incidence of aortic
root reoperation. There was a trend towards better durability using GRF-glue® over
Teflon® felt for aortic root reconstruction.
Chapter 5 describes the initial St. Antonius Hospital experience with the aortic valve
reimplantation technique as published by David. The technique replaces the aortic root
with the exception of the aortic valve. Indications include aneurismal disease of the aortic
root or ascending aorta but also aortic wall destruction due to aortic dissection, all
complicated by (severe) aortic regurgitation. The experience with the first 13 patients was
positive. The preoperative aortic regurgitation is corrected and the patients are functionally
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markedly better postoperatively. Further follow-up of this patient group remains necessary
to evaluate the long-term outcome of this technique. 
All the above techniques avoid oral anticoagulation which is one advantage of reparative
aortic valve surgery. The very long-term incidence of anticoagulation related complications
after mechanical aortic valve replacement is not well known but is an important
consideration, especially if a young adult, who still has a considerable life-expectancy,
needs aortic valve surgery. Chapter 6 therefore analyses the incidence of anticoagulation
related complications in patients who underwent a mechanical aortic valve replacement
between 1963 and 1974. Follow-up was complete at a mean of almost 20 years and revealed
that about half of the patients experienced one anticoagulation related event and 23% more
than one event. The incidence of events was highest the first 5 postoperative years and the
risk for a second event was higher than the risk for a first event. The freedom from a first
anticoagulation related event was 46.8 % at 30 years. About half of the events resulted in
a variable degree of permanent deficit. 
Chapter 7 is a comprehensive discussion in which the results of the presented studies are
correlated with clinical practice. 
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Samenvatting
Hoofdstuk 1 geeft een overzicht over de huidige kennis van de aortaklep en de aortaklep
chirurgie. De anatomie, met inbegrip van de anatomische varianten, wordt besproken. De
verschillende aandoeningen van de aortaklep worden uiteengezet evenals hun beloop en
de indicaties voor interventie. De verschillende chirurgische mogelijkheden worden elk
met hun voor- en nadelen besproken. De opzet van dit proefschrift besluit dit hoofdstuk.
Hoofdstuk 2 bestudeert de resultaten van klepreconstructie bij een prolaberende
tweeslippige aortaklep. Gedurende een periode van acht jaar werden 94 patiënten
geopereerd en gemiddeld vijf jaar gevolgd. De reconstructie was moeilijker te
verwezenlijken bij patiënten met een gedilateerde linker ventrikel. Gedurende de follow-up
dienden 12 patiënten gereopereerd te worden aan de aortaklep maar deze kon bij drie van
hen opnieuw gereconstrueerd worden. Het risico op een reoperatie bleek het hoogst het
eerste jaar na de ingreep en bleef nadien vrij constant op 2% per jaar. Na zeven jaar was
84% van de patiënten vrij van reoperatie. Een mislukking van de reconstructie was
frequenter bij patiënten die na de initiële reconstructie nog resterende aortaklep
insufficiëntie hadden.
Hoofdstuk 3 analyseert de resultaten van aortaklepreconstructie bij een prolaberende
drieslippige aortaklep. De techniek werd toegepast bij 33 patiënten maar mislukte
onmiddellijk bij vijf. Gedurende een gemiddelde follow-up van 4 jaar ondergingen nog
drie patiënten een aortaklep vervanging. Na 5 jaar was 83% van de patiënten met een
geslaagde initiële reconstructie, vrij van reoperatie. Het aantal patiënten was onvoldoende
om eventuele risicofactoren voor reoperatie te kunnen opsporen. 
Hoofdstuk 4 is een analyse van de resultaten van de aortaklepsparende chirurgische
behandeling van acute Type A aorta dissecties met aortawortel destructie. Van 1976 tot
1999 werden 121 patiënten geopereerd. De aortawortel werd op verschillende manieren
gereconstrueerd. De gemiddelde follow-up bedroeg nagenoeg 4 jaar. Tien procent van de
patiëntenpopulatie onderging een aortaklepvervanging maar dit was slechts bij een patiënt
ten gevolge van intrinsieke aortaklep pathologie. Negen patiënten werden gereopereerd
voor aortawortel dilatatie. Het gebruik van fibrine lijm voor de aortawortel reconstructie
en de aanwezigheid van een aortaklep annulus > 27 mm was een significante risico factor
voor reoperatie. Daarnaast was er een positieve invloed van GRF-lijm® ten opzichte van
Teflon® vilt voor de aortawortel reconstructie doch dit was statistisch niet significant. 
Hoofdstuk 5 beschrijft de eerste ervaringen in het St. Antoniusziekenhuis met de aortaklep
reïmplantatie techniek, beschreven door David. Deze techniek vervangt de aortawortel,
met uitzondering van de aortaklep, en is voornamelijk geïndiceerd bij een aneurysma van
de aortawortel en eventueel de aorta ascendens. De techniek kan echter ook aangewend
worden bij patiënten met een Type A aorta dissectie die doorloopt tot in de aortawortel.
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De eerste ervaringen waren positief. De aortaklep insufficiëntie wordt nagenoeg volledig
opgeheven en de patiënten zijn functioneel sterk verbeterd. Verder vervolgen van deze
patiënten blijft geïndiceerd gezien de duurzaamheid van deze techniek nog niet bewezen
werd. 
Alle hoger beschreven technieken vermijden het gebruik van orale anticoagulantia. Dit zou
een belangrijk voordeel kunnen betekenen, bijvoorbeeld indien een jonge patiënt
aortaklepchirurgie dient te ondergaan. Daar de precieze incidentie van anticoagulantia
gerelateerde complicaties op zeer lange termijn niet goed bekend is, analyseert hoofdstuk 6
deze problematiek bij patiënten die tussen 1963 en 1974 een mechanische aortaklep-
vervanging ondergingen. De follow-up was volledig en bedroeg gemiddeld nagenoeg 20
jaar. Gedurende die studieperiode had nagenoeg de helft van de patiënten één anti-
coagulantia gerelateerd event en 23% meer dan één. De incidentie van deze complicatie
was het hoogste gedurende de eerste vijf jaar postoperatief en het risico voor een tweede
event was hoger dan dat voor een eerste event. Na 30 jaar had 46.8% van de patiënten nog
geen anticoagulantia gerelateerde complicatie doorgemaakt. Ongeveer de helft van de
events werden als ‘majeur’ bestempeld daar ze resulteerden in een permanent deficit.
Hoofdstuk 7 is een algemene discussie waarin de resultaten van de hoofdstukken 2 tot en
met 6 bezien worden in het licht van de klinische praktijk. 
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